WO2016013986A1 - Antibiotic compositions for treating bacterial infections - Google Patents
Antibiotic compositions for treating bacterial infections Download PDFInfo
- Publication number
- WO2016013986A1 WO2016013986A1 PCT/SG2015/050235 SG2015050235W WO2016013986A1 WO 2016013986 A1 WO2016013986 A1 WO 2016013986A1 SG 2015050235 W SG2015050235 W SG 2015050235W WO 2016013986 A1 WO2016013986 A1 WO 2016013986A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dry powder
- powder composition
- antibiotic
- composition
- colistin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 196
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 81
- 208000035143 Bacterial infection Diseases 0.000 title abstract description 20
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 125
- 241000894006 Bacteria Species 0.000 claims abstract description 76
- 239000003814 drug Substances 0.000 claims abstract description 62
- 229960002260 meropenem Drugs 0.000 claims description 80
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims description 80
- 229960001225 rifampicin Drugs 0.000 claims description 79
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 79
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical group C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 claims description 70
- 229960004089 tigecycline Drugs 0.000 claims description 70
- 108010078777 Colistin Proteins 0.000 claims description 67
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 claims description 62
- 229960003346 colistin Drugs 0.000 claims description 61
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 claims description 61
- 239000003242 anti bacterial agent Substances 0.000 claims description 56
- 229940088710 antibiotic agent Drugs 0.000 claims description 51
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 claims description 50
- 208000015181 infectious disease Diseases 0.000 claims description 34
- 239000002245 particle Substances 0.000 claims description 32
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims description 29
- 108010040201 Polymyxins Proteins 0.000 claims description 20
- 229960000885 rifabutin Drugs 0.000 claims description 18
- 239000004098 Tetracycline Substances 0.000 claims description 17
- 230000001580 bacterial effect Effects 0.000 claims description 17
- ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 claims description 17
- 229930101283 tetracycline Natural products 0.000 claims description 17
- 235000019364 tetracycline Nutrition 0.000 claims description 17
- 150000003522 tetracyclines Chemical class 0.000 claims description 17
- 229960002180 tetracycline Drugs 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 12
- 210000002345 respiratory system Anatomy 0.000 claims description 11
- 241000588724 Escherichia coli Species 0.000 claims description 10
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 10
- 229940126575 aminoglycoside Drugs 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 229930186147 Cephalosporin Natural products 0.000 claims description 9
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 9
- 229940124587 cephalosporin Drugs 0.000 claims description 9
- 150000001780 cephalosporins Chemical class 0.000 claims description 9
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 8
- 208000019693 Lung disease Diseases 0.000 claims description 8
- 229930182555 Penicillin Natural products 0.000 claims description 8
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims description 8
- 229960003644 aztreonam Drugs 0.000 claims description 8
- 229960005091 chloramphenicol Drugs 0.000 claims description 8
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 8
- 239000003172 expectorant agent Substances 0.000 claims description 8
- 239000010419 fine particle Substances 0.000 claims description 8
- 229940066491 mucolytics Drugs 0.000 claims description 8
- 229940049954 penicillin Drugs 0.000 claims description 8
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 7
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 7
- JSVCEVCSANKFDY-SFYZADRCSA-N carbacephem Chemical compound C1CC(C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)C)[C@H]21 JSVCEVCSANKFDY-SFYZADRCSA-N 0.000 claims description 7
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 7
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 claims description 7
- 229960001907 nitrofurazone Drugs 0.000 claims description 7
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 7
- 229940124530 sulfonamide Drugs 0.000 claims description 7
- 150000003456 sulfonamides Chemical class 0.000 claims description 7
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims description 6
- 108010015899 Glycopeptides Proteins 0.000 claims description 6
- 102000002068 Glycopeptides Human genes 0.000 claims description 6
- 108010028921 Lipopeptides Proteins 0.000 claims description 6
- 206010035664 Pneumonia Diseases 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 241000186359 Mycobacterium Species 0.000 claims description 5
- 201000009267 bronchiectasis Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims description 4
- 239000012620 biological material Substances 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 229960000895 doripenem Drugs 0.000 claims description 4
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims description 4
- 229960002182 imipenem Drugs 0.000 claims description 4
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims description 4
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical class C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 3
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical class C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 3
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical class C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 claims description 3
- 241000589291 Acinetobacter Species 0.000 claims description 3
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 claims description 3
- 241000588921 Enterobacteriaceae Species 0.000 claims description 3
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 claims description 3
- 201000008197 Laryngitis Diseases 0.000 claims description 3
- 239000004100 Oxytetracycline Chemical class 0.000 claims description 3
- 229960002398 demeclocycline Drugs 0.000 claims description 3
- 229960003722 doxycycline Drugs 0.000 claims description 3
- 229960002770 ertapenem Drugs 0.000 claims description 3
- 229960004023 minocycline Drugs 0.000 claims description 3
- 229960000625 oxytetracycline Drugs 0.000 claims description 3
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical class C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 3
- 235000019366 oxytetracycline Nutrition 0.000 claims description 3
- 201000009890 sinusitis Diseases 0.000 claims description 3
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Chemical class C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 3
- 201000008225 Klebsiella pneumonia Diseases 0.000 claims description 2
- 206010035717 Pneumonia klebsiella Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 51
- 238000011282 treatment Methods 0.000 abstract description 18
- 206010059866 Drug resistance Diseases 0.000 abstract description 7
- 230000009467 reduction Effects 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 description 34
- 238000000034 method Methods 0.000 description 20
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 14
- 239000007921 spray Substances 0.000 description 14
- 239000000443 aerosol Substances 0.000 description 12
- 229940112141 dry powder inhaler Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 241000894007 species Species 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000008021 deposition Effects 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 206010021703 Indifference Diseases 0.000 description 9
- 230000000845 anti-microbial effect Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000000654 additive Substances 0.000 description 7
- 230000000996 additive effect Effects 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 229940041011 carbapenems Drugs 0.000 description 7
- 229960003405 ciprofloxacin Drugs 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 229940121375 antifungal agent Drugs 0.000 description 6
- 239000003429 antifungal agent Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 238000001694 spray drying Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- -1 coatings Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000000445 field-emission scanning electron microscopy Methods 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 229960001855 mannitol Drugs 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229940071648 metered dose inhaler Drugs 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000009044 synergistic interaction Effects 0.000 description 4
- 229940072172 tetracycline antibiotic Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Natural products O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000004067 bulking agent Substances 0.000 description 3
- 229960001127 colistin sulfate Drugs 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010610 time kill assay Methods 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 3
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 208000032376 Lung infection Diseases 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 2
- 238000012387 aerosolization Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229960000985 ambroxol hydrochloride Drugs 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 108010068385 carbapenemase Proteins 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001782 cephems Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960004531 colistimethate sodium Drugs 0.000 description 2
- IQWHCHZFYPIVRV-VLLYEMIKSA-I colistin A sodium methanesulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].CC[C@@H](C)CCCCC(=O)N[C@@H](CCNCS([O-])(=O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCNCS([O-])(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCNCS([O-])(=O)=O)NC(=O)[C@H](CCNCS([O-])(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS([O-])(=O)=O)NC1=O IQWHCHZFYPIVRV-VLLYEMIKSA-I 0.000 description 2
- 108700028201 colistinmethanesulfonic acid Proteins 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 229960000860 dapsone Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229960002599 rifapentine Drugs 0.000 description 2
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960000707 tobramycin Drugs 0.000 description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- HBUJYEUPIIJJOS-PBHICJAKSA-N (5r)-3-[4-[1-[(2s)-2,3-dihydroxypropanoyl]-3,6-dihydro-2h-pyridin-4-yl]-3,5-difluorophenyl]-5-(1,2-oxazol-3-yloxymethyl)-1,3-oxazolidin-2-one Chemical compound C1N(C(=O)[C@@H](O)CO)CCC(C=2C(=CC(=CC=2F)N2C(O[C@@H](COC3=NOC=C3)C2)=O)F)=C1 HBUJYEUPIIJJOS-PBHICJAKSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 1
- 241001148231 Acinetobacter haemolyticus Species 0.000 description 1
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
- 241000607528 Aeromonas hydrophila Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 108010064760 Anidulafungin Proteins 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241001135322 Bacteroides eggerthii Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 description 1
- 241000606219 Bacteroides uniformis Species 0.000 description 1
- 241000606215 Bacteroides vulgatus Species 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 241000588780 Bordetella parapertussis Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 241000589513 Burkholderia cepacia Species 0.000 description 1
- 241000589877 Campylobacter coli Species 0.000 description 1
- 241000589874 Campylobacter fetus Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010065839 Capreomycin Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010020326 Caspofungin Proteins 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000588919 Citrobacter freundii Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000918600 Corynebacterium ulcerans Species 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- 241001600125 Delftia acidovorans Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108010049047 Echinocandins Proteins 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 102100021514 HLA class I histocompatibility antigen protein P5 Human genes 0.000 description 1
- 241000606788 Haemophilus haemolyticus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000606822 Haemophilus parahaemolyticus Species 0.000 description 1
- 241000606766 Haemophilus parainfluenzae Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000899151 Homo sapiens HLA class I histocompatibility antigen protein P5 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010021450 Immunodeficiency congenital Diseases 0.000 description 1
- 241001454354 Kingella Species 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000588749 Klebsiella oxytoca Species 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 description 1
- 241001293418 Mannheimia haemolytica Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010021062 Micafungin Proteins 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000588772 Morganella morganii Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241001135232 Odoribacter splanchnicus Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000606210 Parabacteroides distasonis Species 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- NCXMLFZGDNKEPB-UHFFFAOYSA-N Pimaricin Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCC(C)OC(=O)C=CC2OC2CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 NCXMLFZGDNKEPB-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000576783 Providencia alcalifaciens Species 0.000 description 1
- 241000588777 Providencia rettgeri Species 0.000 description 1
- 241000588778 Providencia stuartii Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000168225 Pseudomonas alcaligenes Species 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- KGZHFKDNSAEOJX-WIFQYKSHSA-N Ramoplanin Chemical compound C([C@H]1C(=O)N[C@H](CCCN)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C)C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(N[C@@H](C(=O)N[C@H](CCCN)C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)[C@H](C)O)C=1C=CC(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O)=CC=1)=O)NC(=O)[C@H](CC(N)=O)NC(=O)\C=C/C=C/CC(C)C)C(N)=O)C=1C=C(Cl)C(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=1)C1=CC=CC=C1 KGZHFKDNSAEOJX-WIFQYKSHSA-N 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 1
- 241000192087 Staphylococcus hominis Species 0.000 description 1
- 241000191982 Staphylococcus hyicus Species 0.000 description 1
- 241000191980 Staphylococcus intermedius Species 0.000 description 1
- 241001464905 Staphylococcus saccharolyticus Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241001464947 Streptococcus milleri Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 229930184317 Streptovaricin Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 241000607481 Yersinia intermedia Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- PVNFMCBFDPTNQI-UIBOPQHZSA-N [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] acetate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 3-methylbutanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 2-methylpropanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] propanoate Chemical compound CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(C)=O)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CCC(=O)O[C@H]1CC(=O)N(C)c2cc(C\C(C)=C\C=C\[C@@H](OC)[C@@]3(O)C[C@H](OC(=O)N3)[C@@H](C)C3O[C@@]13C)cc(OC)c2Cl.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)CC(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 PVNFMCBFDPTNQI-UIBOPQHZSA-N 0.000 description 1
- 241000606834 [Haemophilus] ducreyi Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002156 adsorbate Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960003348 anidulafungin Drugs 0.000 description 1
- JHVAMHSQVVQIOT-MFAJLEFUSA-N anidulafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@@H](C)O)[C@H](O)[C@@H](O)C=2C=CC(O)=CC=2)[C@@H](C)O)=O)C=C1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960003623 azlocillin Drugs 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 108700043460 bacteria ModE Proteins 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960003034 caspofungin Drugs 0.000 description 1
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 229940036735 ceftaroline Drugs 0.000 description 1
- ZCCUWMICIWSJIX-NQJJCJBVSA-N ceftaroline fosamil Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(NP(O)(O)=O)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 ZCCUWMICIWSJIX-NQJJCJBVSA-N 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- JDECNKBYILMOLE-CJQFIEQYSA-N chembl1255887 Chemical class O1COC(=C(C)C2=O)C3=C1\C(C)=C\[C@@](C)(O)[C@H](O)[C@@H](C)[C@@H](O)[C@H](C(=O)OC)[C@H](O)[C@H](C)[C@H](O)[C@H](C)\C=C/C=C(C)/C(=O)NC1=C(C)C(OC(C)=O)=C3C2=C1O JDECNKBYILMOLE-CJQFIEQYSA-N 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960004287 clofazimine Drugs 0.000 description 1
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 108010040131 decaplanin Proteins 0.000 description 1
- SJSZMXQSCZCGFO-UHFFFAOYSA-N decaplanin Chemical compound C=1C2=CC=C(O)C=1C1=C(O)C=C(O)C=C1C(C(O)=O)NC(=O)C1NC(=O)C2NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC(C=3OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(C)O4)O)=CC2=CC=3OC(C=C2)=CC=C2C1OC1CC(C)(N)C(O)C(C)O1 SJSZMXQSCZCGFO-UHFFFAOYSA-N 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960004100 dirithromycin Drugs 0.000 description 1
- WLOHNSSYAXHWNR-NXPDYKKBSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-NXPDYKKBSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 229960002001 ethionamide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960004273 floxacillin Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 1
- 244000000058 gram-negative pathogen Species 0.000 description 1
- 244000000059 gram-positive pathogen Species 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229960001977 loracarbef Drugs 0.000 description 1
- JAPHQRWPEGVNBT-UTUOFQBUSA-N loracarbef Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C([O-])=O)=O)[NH3+])=CC=CC=C1 JAPHQRWPEGVNBT-UTUOFQBUSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229960003640 mafenide Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
- 229960002159 micafungin Drugs 0.000 description 1
- PIEUQSKUWLMALL-YABMTYFHSA-N micafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS(O)(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 PIEUQSKUWLMALL-YABMTYFHSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- CWQXQMHSOZUFJS-UHFFFAOYSA-N molybdenum disulfide Chemical compound S=[Mo]=S CWQXQMHSOZUFJS-UHFFFAOYSA-N 0.000 description 1
- 229940076266 morganella morganii Drugs 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- YKQOSKADJPQZHB-QNPLFGSASA-N n-[(1s)-3-amino-1-{[(1s,2r)-1-{[(1s)-3-amino-1-{[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl]carbamoyl}propyl]carbamoyl}-2- Chemical compound CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O YKQOSKADJPQZHB-QNPLFGSASA-N 0.000 description 1
- YKQOSKADJPQZHB-YNWHQGOSSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1s)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Polymers CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O YKQOSKADJPQZHB-YNWHQGOSSA-N 0.000 description 1
- 229960003808 nadifloxacin Drugs 0.000 description 1
- JYJTVFIEFKZWCJ-UHFFFAOYSA-N nadifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)CCC3=C1N1CCC(O)CC1 JYJTVFIEFKZWCJ-UHFFFAOYSA-N 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- 229930189656 naphthomycin Natural products 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008025 pharmaceutical bulking agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229940116254 phosphonic acid Drugs 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229930001118 polyketide hybrid Natural products 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229940041153 polymyxins Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229960001589 posaconazole Drugs 0.000 description 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 1
- 229950004447 posizolid Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229950009965 radezolid Drugs 0.000 description 1
- BTTNOGHPGJANSW-IBGZPJMESA-N radezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C1=CC=C(C=2C=CC(CNCC=3NN=NC=3)=CC=2)C(F)=C1 BTTNOGHPGJANSW-IBGZPJMESA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 229950003551 ramoplanin Drugs 0.000 description 1
- 108010076689 ramoplanin Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- 229960003040 rifaximin Drugs 0.000 description 1
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 229940115939 shigella sonnei Drugs 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 229960004954 sparfloxacin Drugs 0.000 description 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229940037649 staphylococcus haemolyticus Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940041022 streptomycins Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000005737 synergistic response Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- XFALPSLJIHVRKE-GFCCVEGCSA-N tedizolid Chemical compound CN1N=NC(C=2N=CC(=CC=2)C=2C(=CC(=CC=2)N2C(O[C@@H](CO)C2)=O)F)=N1 XFALPSLJIHVRKE-GFCCVEGCSA-N 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- 229960005240 telavancin Drugs 0.000 description 1
- ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 description 1
- 108010089019 telavancin Proteins 0.000 description 1
- 229960003250 telithromycin Drugs 0.000 description 1
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 description 1
- 229960001114 temocillin Drugs 0.000 description 1
- BVCKFLJARNKCSS-DWPRYXJFSA-N temocillin Chemical compound N([C@]1(OC)C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C=1C=CSC=1 BVCKFLJARNKCSS-DWPRYXJFSA-N 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960005041 troleandomycin Drugs 0.000 description 1
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention generally relates to the fields of microbiology, biotechnology, and inhalation aerosols. More specifically, the present invention relates to dry powder compositions for the treatment of bacterial infections, such as multi-drug resistant bacterial infections.
- MRSA methicillin-resistant Staphylococcus aureus
- VRE vancomycin-resistant enterococci
- Acinetobacter baumannii Pseudomonas aeruginosa and Enterobacteriaceae (including Klebsiella pneumoniae and Escherichia coli), among the Gram-negative bacteria.
- Gram-negative bacteria are more resistant to antibiotics than Gram-positive bacteria due to the presence of a second outer membrane, which provides an efficient barrier to both hydrophilic and hydrophobic compounds. Consequently, Gram-negative bacterial infections are typically more problematic to treat in view of the fewer classes of antibiotics available for effective treatment.
- carbapenems for example, imipenem, meropenem and doripenem
- carbapenems possess broad- spectrum activity against many Gram-negative bacteria they remain the 'final-line' drug of choice for extended- spectrum, ⁇ -lactamase-producing organisms.
- carbapenem-resistant and carbapenemase-producing organisms are "superbugs", exhibiting broad resistance to many other antibiotic classes, often leaving the infection untreatable).
- seeking alternative treatment regimens has become a pressing issue.
- colistin a 50-year old polymyxin class of antibiotics
- colistin is undergoing a period of revival, and is favored as a 'last line' therapeutic against these hard to treat multidrug- resistant bacteria, such as P. aeruginosa, A. baumannii and K. pneumoniae.
- sporadic reports of colistin-resistant strains have started emerging from various parts of the world (for example, Singapore, Greece, Israel and South Korea).
- Combination regimens are therefore attractive alternative strategies to overcoming these rising rates of drug resistance in the dearth of newer antibiotics.
- Inhaled delivery of these combination compounds are useful in eradicating these pathogens more effectively due to direct lung targeting at high minimum inhibitory concentrations (MICs).
- MICs minimum inhibitory concentrations
- the simultaneous use of multiple classes of antibiotics is also useful in protecting against the re-emergence of drug resistant bacteria. As such, there is a need in the art for antibiotic compositions that are effective in the treatment of infections by multi-drug resistant bacteria, and the subsequent reduction in the prevalent rates of drug resistance.
- a dry powder composition comprising: a polymyxin antibiotic; and at least one further antibiotic selected from the group consisting of an aminoglycoside, an ansamycin, a carbacephem, a carbapenem, a cephalosporin, a glycopeptide, a lincosamide, a lipopeptide, a macrolide, a monobactam, a nitrofuran, a oxazolidonone, a penicillin, a polypeptide, a quinolone, a sulfonamide, a tetracycline, a chloramphenicol, a phosphonic acid antibiotic and a mycobacteria antibiotic.
- a polymyxin antibiotic selected from the group consisting of an aminoglycoside, an ansamycin, a carbacephem, a carbapenem, a cephalosporin, a glycopeptide, a lincosamide, a lipopeptide, a macrol
- a dry powder composition as described herein in the manufacture of a medicament for treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium.
- a dry powder composition as described herein in the manufacture of a medicament for treating a respiratory system infection by a bacterium.
- Fig.l shows the different mechanisms of action of the antibiotic combinations of the present invention.
- Fig. 2 shows the Field Emission Scanning Electron Microscopy (FESEM) images of the spray dried powders of a) SD-COL/TGC/RIF; b) SD-COL/MEM/TGC; c) SD- COL/MEM/RIF; d) SD-COL; e) SD-TGC; f) SD-MEM and g) SD-RIF.
- Fig. 3 shows In vitro deposition of the co-spray dried ternary formulation SD-COL/TGC/RIF at 60 L/min of airflow.
- Fig. 4 shows In vitro deposition of the co-spray dried ternary formulation SD- COL/MEM/TGC at 60 L/min of airflow.
- Fig. 5 shows In vitro deposition of the co-spray dried ternary formulation SD- COL/MEM/RIF at 60 L/min of airflow.
- NGI Next Generation Impactor
- Stages 1-7 impactor stages, with the corresponding aerodynamic cutoff diameter in parentheses
- MOC NGI micro-orifice collector.
- Fig. 6 shows In vitro deposition of the spray dried individual species at 60 L/min of airflow, (a) SD-COL, (b) SD-MEM, (c) SD-TGC, (d) SD-RIF.
- Fig. 7 shows the X-Ray diffraction patterns of SD-COL/MEM/RIF, SD-COL/MEM/TGC, SD-COL/TGC/RIF and their spray-dried individuals.
- composition in the context of the present invention refers to a combination of antibiotics optionally containing other components, such as carriers, excipients, diluents, isotonic solutions, buffers and the like.
- formulation means a specific composition formulated for specific use, such as for aerosolization of an antibiotic in either the dry powdered, solution or suspension form.
- the term “antibiotic” refers to a natural or synthetic substance that has the capacity to inhibit the growth of, or to kill other microorganisms.
- microorganism refers to prokaryotic and eukaryotic cells, which grow as single cells, or when growing in association with other cells, do not form organs (for examples microorganisms include bacteria, yeast, molds, and fungi).
- the language "pharmaceutically acceptable carrier” is intended to include solvents, dispersion media, coatings, anti-bacterial and anti-fungal agents, isotonic and absorption delaying agents, and the like.
- the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the compound, use thereof in the therapeutic compositions and methods of treatment and prophylaxis is contemplated. Supplementary active compounds may also be incorporated into the compositions according to the present invention.
- treatment refers to any and all uses which remedy an infection, disease state or symptoms, prevent the establishment of disease, or otherwise prevent, hinder, retard, or reverse the progression of an infection or disease or other undesirable symptoms in any way whatsoever.
- the terms “treat,” or “treating,” refers to administering a medicament for prophylactic and/or therapeutic purposes.
- prophylactic treatment refers to treating a subject who is not yet infected, but who is susceptible to, or otherwise at risk of, a particular infection such that there is a reduced onset of infection. Treatment may eliminate the infection, or it may reduce the bacterial load in the tissues that results in improvements measured by a subject's symptoms or measures of lung function.
- bacterial infection refers to the undesired proliferation or presence of invasion of bacteria in a host organism or subject. This includes the excessive growth of bacteria that are normally present in or on the body of a mammal or other organisms. More generally, a bacterial infection can be any situation in which the presence of a bacteria population(s) is damaging to a subject. Thus, a bacterial infection exists when excessive numbers of a bacterial population are present in or on a subject's body, or when the effects of the presence of a bacterial population(s) is damaging the cells or other tissue of a subject.
- drug resistant when used in reference to bacterium refers to a bacterium that is resistant to the antimicrobial activity of a drug, such as an antibiotic. Drug resistance may also be referred to as antibiotic resistance. In some cases, a bacterium that is generally susceptible to a particular antibiotic can develop resistance to the antibiotic, thereby becoming a drug resistant bacterium.
- a "multi-drug resistant" bacterium is one that is resistant to more than one drug having antimicrobial activity.
- One skilled in the art can readily determine if a microbe is drug resistant using routine laboratory techniques that determine the susceptibility or resistance of a bacterium to a drug or antibiotic.
- the term "synergistic effect” refers to a larger therapeutic effect of the combined antibiotics of the formulations disclosed in comparison to the effect predicted from the sum of each antibiotic alone.
- the present invention provides a novel antibiotic composition for the treatment of bacterial infections, respiratory diseases and pulmonary infections. More particularly, the present invention and antibiotic composition represents a novel and timely intervention in the fight against multi-resistant bacteria.
- Antibiotics that may be used in the present invention include, but are not limited to broad- spectrum antibiotics (for example, tetracyclines); medium- spectrum antibiotics (for example, bacitracin, erythromycins, penicillin, cephalosporins and streptomycins); and narrow spectrum antibiotics (for example, antibiotics that are effective against only a few species of bacteria, for example, polymyxins).
- broad- spectrum antibiotics for example, tetracyclines
- medium- spectrum antibiotics for example, bacitracin, erythromycins, penicillin, cephalosporins and streptomycins
- narrow spectrum antibiotics for example, antibiotics that are effective against only a few species of bacteria, for example, polymyxins.
- the antibiotics that may be used in the present invention are selected from an antibiotic family or class including but not limited to aminoglycoside, ansamycin, carbacephem, carbapenem, cephalosporin, glycopeptide antibiotic, lincosamide, lipopeptide, macrolide, monobactam, nitrofuran, oxazolidonone, penicillin, polymyxin, polypeptide antibiotic, quinolone, sulfonamide, tetracycline, chloramphenicol, phosphonic acid antibiotic and mycobacteria antibiotic.
- the antibiotic families described herein and their specific subclasses of antibiotics are well defined and known in the art by the skilled artisan. Nevertheless, the following non-limiting examples of specific antibiotics that are categorized under each family are defined in the below Table 1.
- cephalosporin cephalexin cephalexin, cefadroxil, cefdinir, cefoxitin, cefaclor, ceftaroline and cefixime
- glycopeptide A class of drugs of microbial origin that are composed of glycosylated cyclic or polycyclic nonribosomal peptides, and may include but not limited to vancomycin, teicoplanin, telavancin, ramoplanin and decaplanin
- polymyxin colistin polymyxin B
- analogues or variants of the antibiotics listed in Table 1 may be used in the present invention. These antibiotics may be referred to as "functional analogues or variants" that maintain the antibiotic activity as compared to the reference antibiotic.
- the functional analogue or variant antibiotics may be found in nature or be an engineered mutant thereof.
- the antibiotic activity of the analogues or variants may be readily determined by well-known methods and techniques in the art.
- two or more antibiotics may be used in combination.
- three or more antibiotics may be used in combination, and preferably three antibiotics may be used in combination.
- a combination of three antibiotics may be referred to as a ternary drug combination.
- the combination of antibiotics is formulated into a composition.
- the present invention provides a composition comprising at least two or at least three antibiotics selected from the group consisting a polymyxin, an aminoglycoside, an ansamycin, a carbacephem, a carbapenem, a cephalosporin, a glycopeptide, a lincosamide, a lipopeptide, a macrolide, a monobactam, a nitrofuran, a oxazolidonone, a penicillin, a polypeptide, a quinolone, a sulfonamide, a tetracycline, a chloramphenicol, a phosphonic acid antibiotic and a mycobacteria antibiotic.
- antibiotics selected from the group consisting a polymyxin, an aminoglycoside, an ansamycin, a carbacephem, a carbapenem, a cephalosporin, a glycopeptide, a lincosamide, a lipopeptide,
- an antibiotic comprised in the composition is a polymyxin.
- the composition comprises a polymyxin antibiotic; and at least one further antibiotic selected from the group consisting of an aminoglycoside, an ansamycin, a carbacephem, a carbapenem, a cephalosporin, a glycopeptide, a lincosamide, a lipopeptide, a macrolide, a monobactam, a nitrofuran, a oxazolidonone, a penicillin, a polypeptide, a quinolone, a sulfonamide, a tetracycline, a chloramphenicol, a phosphonic acid antibiotic and a mycobacteria antibiotic.
- the polymyxin is colistin (polymyxin E). In one embodiment, the colistin is colistin sulphate.
- the at least one further antibiotic is selected from the group consisting of a carbapenem, an ansamycin and a tetracycline.
- the carbapenem is selected from the group consisting of ertapenem, doripenem, imipenem and meropenem. In a preferred embodiment, the carbapenem is meropenem.
- the ansamycin is rifampicin.
- the tetracycline is selected from the group consisting of demeclocycline, doxycycline, minocycline, oxytetracycline and tetracycline analogues. In a preferred embodiment, the tetracycline is tigecycline.
- the composition comprises three antibiotics.
- the composition comprises a polymyxin antibiotic, an ansamycin antibiotic and a tetracycline antibiotic.
- the composition comprises colistin, tigecycline and rifampicin.
- the composition comprises a polymyxin antibiotic, a tetracycline antibiotic and a carbapenem antibiotic.
- the composition comprises colistin, meropenem and tigecycline.
- the composition comprises a polymyxin antibiotic, an ansamycin antibiotic and a carbapenem antibiotic.
- the composition comprises colistin, meropenem and rifampicin.
- composition may be formulated with one or more components.
- the selection of the one or more components may be readily chosen by the skilled artisan based upon the formulation of the composition and route of administration. The suitability of the one or more components may be readily known by those skilled in the art or may be determined using well-known techniques.
- the one or more components may comprise excipients, antibiotics, a pharmaceutically acceptable carrier, a mucolytic agent, an anti-inflammatory agent, or pharmaceutically active ingredients.
- the composition may comprise one or more components which are commonly used in the preparation of a dry powder formulation, such as an excipient.
- the one or more components may comprise an excipient.
- excipients are used to enhance the physical or chemical stability of the active ingredient, and its mechanical properties, and/or its pharmaceutical properties, such as dissolution and permeation.
- excipients function as carrier particles to reduce drug cohesiveness by occupying the high-energy sites of the drug particles.
- carrier particles may include sugars or sugar alcohols such as mannitol, lactose, glucose, sorbitol, trehalose, raffinose or dextrose.
- sugars or sugar alcohols such as mannitol, lactose, glucose, sorbitol, trehalose, raffinose or dextrose.
- excipients may be phospholipids, such as phosphatidylcholine and cholesterol; lubricants that reduce drug cohesion and adhesion, such as leucine, magnesium stearate, sodium stearate, polyethylene glycol; polymers that act as drug release modifiers or formulation stability enhancers, such as chitosan, polyvinyl alcohol, polylactic-co-glycolic acid; sugar polymers, such as dextran, dextrin; or stabilizers, such as tocopherol, cyclodextrins, polymers, albumins, antioxidants, surfactants and salts. Excipients may make up over 99% of the dry powder inhaler formulation by weight.
- Physiochemical properties of the excipient such as size and morphology may affect the performance of the dry powder formulation.
- the adhesive forces of the formulation may also be considered, wherein inadequate separation of the active ingredient and carrier is the main reason for deposition problems.
- the excipient may be modified before combining it with the compositions of the present invention. It should also be appreciated that excipients are not always required.
- the one or more components may comprise a mucolytic agent and/or an anti-inflammatory agent.
- a mucolytic agent helps to loosen and clear mucus from an airway that has been infected by a bacteria or virus.
- the mucolytic agent may include a lysozyme, ambroxol hydrochloride, sodium chloride, N-acetylcysteine, or mannitol.
- An antiinflammatory agent reduces infection severity and may include a steroid or a non-steroidal anti-inflammatory drug, such as aspirin, ibuprofen, naproxen. It is also possible to use more than one mucolytic agent or anti-inflammatory agent in the composition.
- the one or more components may comprise pharmaceutically active ingredients.
- the formulation may comprise a pharmaceutical composition used for treating lung cancer, steroids (for example, budesonide), beta-2-agonists (for example, salbutamol sulphate), anticholinergics (for example, ipratropium bromide), mucolytic agents (for example, lysozyme, ambroxol hydrochloride), substances added to improve wound healing (for example, heparin), anti-histimine (for example, cetrizine hydrochloride) or decongestants (for example, pseudoephedrine).
- steroids for example, budesonide
- beta-2-agonists for example, salbutamol sulphate
- anticholinergics for example, ipratropium bromide
- mucolytic agents for example, lysozyme, ambroxol hydrochloride
- substances added to improve wound healing for example, heparin
- anti-histimine for example, cetrizine hydrochloride
- the one or more components may comprise anti-fungal agents to target mixed pathogen populations.
- the anti-fungal agents may include but are not limited to polyene anti-fungal agents (for example, Amphotericin B, Nystatin or Pimaricin), azole anti- fungal agents (for example, Posaconazole, Voriconazole, Fluconazole or Itraconazole), or Echinocandin anti-fungal agents (for example, Caspofungin, Micafungin or Anidulafungin).
- the one or more components may comprise anti-cancer drugs for concurrent cancer, and bacterial or mixed infection therapy, whereby a weakened immune system and hence an increased risk for pathogenic infections is a common occurrence during the cancer treatment.
- the anti-cancer drugs may include but are not limited to Cisplatin, Paclitaxel, Doxurubicin, Methotrexate, Carboplatin or Gemcitabine.
- the one or more components may comprise a pharmaceutically acceptable carrier.
- the carrier may include, for example, one or more of the following: suspension aids, desiccants, diluents, stabilizers, glidants, binders, fillers and bulking agents, and the like.
- the filler material and bulking agents may comprise about 10 to 95% of the composition.
- the filler(s) will make up about 60 to 85% of the composition.
- Filler material can include any inert pharmaceutical bulking agent or material.
- microcrystalline cellulose is utilized.
- mannitol is highly efficacious as a filler/bulking agent.
- Silicon dioxide also has excellent bulking properties. It is desirable that a combination of microcrystalline cellulose, mannitol and silicon dioxide be provided.
- the composition disclosed herein may comprise one or more components selected from the group consisting of excipients, antibiotics, a pharmaceutically acceptable carrier, a mucolytic agent, an anti-inflammatory agent, and pharmaceutically active ingredients.
- the one or more components is suitable for oral or nasal administration.
- compositions described herein may be prepared in the form of a dry powder. Accordingly, in one embodiment the composition described herein is a dry powder composition.
- the composition described herein may be milled, precipitated, spray dried or otherwise processed to particle sizes between about 1 and 5 ⁇ in preparing the dry powder composition.
- the composition described herein may be prepared to a powder having particles with volume median diameters (d 5 o) ranging from 1-10 ⁇ , more preferably 0.1-7 ⁇ , 0.1-5 ⁇ or 0.5-5 ⁇ , by media milling, jet milling, spray drying or particle precipitation techniques that are readily known in the art.
- the volume median diameter (d 5 o) of the particles in the dry powder composition is in the range of 0.5-10 ⁇ , and preferably in the range of 1-5 ⁇ .
- the dry powder composition is prepared by spray-drying.
- spray-drying uses methods conventionally known in the art and involves spraying a fine mist of the composition through a nozzle and into a hot vapor stream. The particles are dried in the process and are then collected. It will be readily appreciated by the skilled artisan that techniques suitable for preparation of dry powders and any and all improvements thereof are intended to be within the scope of the invention.
- the present invention provides a dry powder composition
- a polymyxin antibiotic comprising a polymyxin antibiotic; and at least one further antibiotic selected from the group consisting of an aminoglycoside, an ansamycin, a carbacephem, a carbapenem, a cephalosporin, a glycopeptide, a lincosamide, a lipopeptide, a macrolide, a monobactam, a nitrofuran, a oxazolidonone, a penicillin, a polypeptide, a quinolone, a sulfonamide, a tetracycline, a chloramphenicol, a phosphonic acid antibiotic and a mycobacteria antibiotic.
- a polymyxin antibiotic selected from the group consisting of an aminoglycoside, an ansamycin, a carbacephem, a carbapenem, a cephalosporin, a glycopeptide, a lincosamide
- any effective weight ratio of the antibiotics in the composition may be used.
- the weight ratio of the antibiotics in the dry powder composition will depend on the particular dosing regimen, and how much of each of the particular antibiotics is to be included in the final dose.
- the weight ratio of the polymyxin antibiotic to the at least one further antibiotic may be in the range from about 1:5 to about 5: 1; or from about 1: 1 to about 2:1, preferably from about 1:4 to about 4: 1, more preferably from about 1:3 to about 3: 1. In one embodiment, the weight ratio of the polymyxin antibiotic to the at least one further antibiotic may be 5:4 or 5: 12.
- the dry powder composition comprises three antibiotics.
- the dry powder composition comprises a polymyxin antibiotic, an ansamycin antibiotic and a tetracycline antibiotic in a weight ratio of about 5:4: 12.
- the dry powder composition comprises colistin, tigecycline and rifampicin in a weight ratio of about 5:4: 12.
- the dry powder composition comprises a polymyxin antibiotic, a tetracycline antibiotic and a carbapenem antibiotic in a weight ratio of about 5:4:4.
- the dry powder composition comprises colistin, meropenem and tigecycline in a weight ratio of about 5:4:4.
- the dry powder composition comprises a polymyxin antibiotic, an ansamycin antibiotic and a carbapenem antibiotic in a weight ratio of about 5:4: 12.
- the dry powder composition comprises colistin, meropenem and rifampicin in a weight ratio of about 5:4: 12.
- the dry powder compositions of the present invention and antibiotic combinations may exhibit a therapeutic effect indifferent, additive or larger than the effect predicted from the sum of each antibiotic alone. In one embodiment, the dry powder composition described herein may exhibit a therapeutic effect larger than the effect predicted from the sum of each antibiotic alone. In one embodiment, the dry powder composition described herein exhibits a synergistic effect.
- Convenient modes of administration of the dry powder composition described herein may include injection (for example subcutaneous or intravenous administration), oral administration, inhalation, or transdermal administration.
- the dry powder composition may be coated with a material for protection from the action of enzymes, acids and other natural conditions which may inactivate the therapeutic activity of the compound.
- the administration of the dry powder compositions disclosed herein may be via any of the accepted modes of administration including, but not limited to nasal, oral, transdermal, subcutaneous or intravenous. These modes of administration refer to the conventional routes of administration and are readily understood by the skilled artisan based upon the intended use and composition.
- the dry powder composition is formulated to be administered nasally, orally, transdermally, subcutaneously or intravenously.
- the dry powder composition is formulated to be administered by an inhaler, a syringe, an implantable device, a medically inserted device or a biomaterial.
- the dry powder composition may be reconstituted as an injectable suspension for administration by injection.
- the implantable device and medically inserted device or biomaterial are those readily known to the skilled artisan for delivery of antibiotics.
- a medically inserted device may comprise a catheter; and an implantable device or biomaterial may comprise a prosthesis, an artificial heart valve, a breast implant or a dental implant.
- the dry powder compositions described herein may be suitably formulated into solid, semi-solid, liquid and aerosol dosage forms, such as liquids, suspensions, complexations, liposomes or particulates.
- the dry powder compositions may, for example, be prepared as a liquid by dissolving, dispersing, the composition described herein in a carrier (e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol or the like) to form a solution or suspension.
- a carrier e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol or the like
- Solutions to be aerosolized can be prepared in conventional forms, either as liquid solutions or suspensions, as emulsions, or in solid forms suitable for dissolution or suspension in liquid prior to aerosol production and inhalation.
- the dry powder composition is administered by injection.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
- solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
- the dry powder composition described herein is formulated to be inhaled by the subject either through nasal or oral administration for delivery to a subject's respiratory tract.
- the inhalation of the dry powder composition described herein may be via the mouth and throat.
- the compositions described herein are dry powder inhalation compositions.
- the dry powder composition does not require any further handling such as diluting of the dry powder, and thus is practical and convenient.
- the compositions described herein be prepared as a dry powder inhalation composition with the advantage of being both practical and convenient because it does not require dilution or other handling, it has an extended shelf-life and storage stability and the dry powder inhalation delivery devices are portable and do not require an air compressor needed by aerosol nebulizers.
- the administration of the dry powder inhalation composition to the upper airways may be avoided in favor of the middle and lower airways of the respiratory tract.
- the dry powder inhalation compositions may be endobronchial ⁇ administered for efficacious delivery of the antibiotic composition into the endobronchial space.
- particles of the dry powder compositions having an aerodynamic diameter of greater than about 5 microns generally do not reach the lung; instead, they tend to impact the back of the throat and are swallowed and possibly orally absorbed.
- Particles having diameters of about 2 to about 5 microns are small enough to reach the upper- to mid- pulmonary region (conducting airways), but are too large to reach the alveoli. Smaller particles, i.e., about 0.5 to about 2 microns, are capable of reaching the alveolar region. Particles having diameters smaller than about 0.5 microns can also be deposited in the alveolar region by sedimentation, although very small particles may be exhaled.
- a dry powder inhalation composition has potency, on a mass basis, which allows delivery of the compositions described herein through the use of a dry powder inhaler.
- the dry powder composition may be administered by devices that are sufficiently small, fully portable and do not require, for example, an air compressor which is needed for a jet nebulizer. Additionally, the dry powder composition has a longer shelf life than liquid compositions for aerosolization.
- the dry powder inhalation composition described herein is administered via an inhalation device.
- the dry powder composition may be administered by dry powder inhalers, nebulizers or metered dose inhaler.
- the dry powder composition may be reconstituted into a suspension.
- the dry powder inhalation composition described herein is administered via a dry powder inhaler.
- the dry powder inhaler may be designed for single use or multiple use or as a re-usable or disposable inhaler.
- the emitted dose (ED) of the dry powder inhalation composition described herein is the total mass of the antibotics emitted from the inhalation device following actuation. It does not include the material left on the internal or external surfaces of the device, or in the metering system including, for example, the capsule or blister.
- the dry powder inhaler may disperse the dry powder formulation at a rate between about 30 to about 100 L/min, 30 to about 80 L/min, 30 to about 70 L/min, 40 to about 90 L/min, 30 to about 60 L/min, 40 to about 70 L/min, 50 to about 70 L/min, 30 L/min, 40 L/min, 50 L/min, 60 L/min or 70 L/min. Administration at these rates can achieve a substantially uniform deposition profile across all impaction stages.
- the fine particle dose (FPD) is the total mass of active agent which is emitted from the device following actuation which is present in an aerodynamic particle size smaller than a defined limit.
- the FPD and ED are both measured using an impactor or impinger, such as a twin stage impinger (TSI), multi-stage liquid impinger (MSLI), Andersen Cascade Impactor (ACI) or a Next Generation Impactor (NGI).
- TSI twin stage impinger
- MSLI multi-stage liquid impinger
- ACI Andersen Cascade Impactor
- NTI Next Generation Impactor
- Each impactor or impinger has a pre-determined aerodynamic particle size collection cut point for each stage.
- the FPD value is obtained by interpretation of the stage-by- stage active agent recovery quantified by a validated quantitative wet chemical assay where either a simple stage cut is used to determine FPD or a more complex mathematical interpolation of the stage-by-stage deposition is used.
- the fine particle fraction represents the mass fraction of drug particles smaller than 5 ⁇ in the aerosol cloud (FPD) relative to the total mass recovered and may be obtained by interpolation to the cumulative percent under size at 5 ⁇ . FPF (emitted) may be obtained when the FPD is expressed relative to the ED.
- the dry powder inhalation composition has a fine particle fraction (FPF) of at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, or at least 70%. In one embodiment, the dry powder inhalation composition has a fine particle fraction of at least 50%.
- compositions described herein may be administered with a frequency of about 1, 2, 3, 4, or more times daily, 1, 2, 3, 4, 5, 6, 7 or more times weekly, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times monthly. In one embodiment, the compositions are administered twice daily. Single or multiple administrations of the compositions according to the invention may be carried out.
- One skilled in the art would be able, by routine experimentation, to determine effective, non-toxic dosage levels of the composition of the invention and an administration pattern which would be suitable for treating the diseases and/or infections to which the compositions are applicable.
- the dry powder compositions described herein may be used to treat bacterial infections in a subject.
- the subject may be an animal, and in particular a mammal.
- mammal is used in its usual biological sense and includes humans, cattle, horses, dogs, and cats, but also includes many other species.
- the bacterial infection may be derived from a bacterium selected from the group consisting of Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonas putida, Stenotrophomonas maltophilia, Aeromonas hydrophilia, Escherichia coli, Citrobacter freundii, Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Provide
- the bacterium is selected from the group consisting of Bacteroides fragilis, Bacteroides distasonis, Bacteroides 3452A homology group, Bacteroides vulgatus, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii, Bacteroides splanchnicus, Corynebacterium diphtheriae, Corynebacterium ulcerans, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus milleri; Streptococcus (Group G); Streptococcus (Group C/F); Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus intermedius
- the bacterium is an acid-fast bacterium.
- the lung bacterium is selected from the group consisting of Mycobacterium tuberculosis, and non- tuberculous Mycobacterium including Mycobacterium avium, Mycobacterium intracellular, Mycobacterium abscesses and Mycobacterium leprae.
- the bacterium is a Gram-negative bacterium selected from the group consisting of Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii- calcoaceticus complex and Mycobacterium species.
- the bacterium is a Gram-negative bacterium, a Gram-positive bacterium or an acid-fast bacterium. In another embodiment, the bacterium is a multidrug resistant bacterium.
- the present invention provides the use of a dry powder composition described herein in the manufacture of a medicament for treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium.
- a subject may be identified as "infected” or "suspected to be infected” with multidrug resistant bacterium by virtue of the subject having symptoms that are characteristic of a bacterial infection with a bacteria species known to have resistant strains or with a bacteria that is a member of groups that are known to have resistant strains.
- the bacteria may be isolated from the subject, cultured and identified as a bacteria species known to have resistant strains or a bacteria that is a member of group that are known to have resistant strains.
- a subject may be identified as "at risk of infection" with multidrug resistant bacterium by the subject having a wound or a condition or a disease that improves the possibility and occurrence of a bacterial infection, such patients at risk for infection are selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients.
- a subject may be identified as "at risk of infection" with multidrug resistant bacterium if the subject visits or resides in a location known to be, or likely to be, colonized with multidrug resistant bacterium, such as a medical facility where multi-drug resistant Staphylococcus aureus (MDRSA) and multi-drug resistant Pseudomonas species may be present.
- MDRSA multi-drug resistant Staphylococcus aureus
- Pseudomonas species may be present.
- the bacterial infection may be a respiratory system infection such as a pulmonary infection.
- the present invention provides the use of a dry powder composition described herein in the manufacture of a medicament for treating a respiratory system infection by a bacterium.
- the bacterium is a multidrug resistant bacterium.
- the bacterial respiratory system infection is laryngitis, bronchitis, pneumonia, or sinusitis.
- the present invention provides the use of a dry powder composition described herein in the manufacture of a medicament for treating a pulmonary disease or condition.
- a dry powder composition described herein can include cystic fibrosis, and chronic obstructive pulmonary disease (COPD), including chronic bronchitis, bronchiectasis and some asthmas.
- COPD chronic obstructive pulmonary disease
- the pulmonary disease or condition is cystic fibrosis, bronchiectasis or chronic obstructive pulmonary disease (COPD).
- the dry powder compositions described herein may be applied to a method for treating a bacterial infection in a subject, in particular for treating respiratory system infections.
- the dry powder compositions described herein may be applied to a method for treating a pulmonary disease or condition.
- this method may be used to administer the dry powder composition to the site of infection.
- Such a method may reduce systemic exposure and maximizes the amount of dry powder composition to the site of bacterial infection.
- the present invention provides a method of treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium, comprising administering to the subject a dry powder composition as described herein.
- a method of treating a respiratory system infection by a bacterium in a subject comprising administering to the subject a dry powder composition as described herein.
- the bacterium is a multidrug resistant bacterium.
- the multidrug resistant bacterium is selected from the group consisting of Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumonia and Escherichia coli.
- the bacterial respiratory system infection is laryngitis, bronchitis, pneumonia, or sinusitis.
- a method of treating a pulmonary disease or condition in a subject comprising administering to the subject a dry powder composition as described herein.
- the pulmonary disease or condition is cystic fibrosis, bronchiectasis, or chronic obstructive pulmonary disease (COPD).
- COPD chronic obstructive pulmonary disease
- the amount of the respective antibiotics in the dry powder compositions to be administered will, of course, be dependent on the subject and disease state being treated, the severity of the affliction, the manner and schedule of administration and the judgment of the prescribing physician.
- the invention illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein.
- the terms “comprising”, “including”, “containing”, etc. shall be read expansively and without limitation.
- the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed.
- Rifampicin was obtained from Leshan Sanjiu-Longmarch Pharmaceuticals Co., Ltd.
- Colistin sulfate was purchased from Sigma Chemical Co. (Louis, MO, USA).
- the drug ratios developed were first derived from in vitro susceptibility studies against control strains and guided by EUCAST (European Committee on Antimicrobial Susceptibility Testing) susceptibility breakpoints.
- EUCAST European Committee on Antimicrobial Susceptibility Testing
- the spray-dried powders were stored in a desiccator at room temperature for further characterization.
- Colistin sulfate (instead of colistimethate sodium) is chosen as colistin sulfate is more stable than colistimethate sodium in human plasma.
- the morphology of the powder particles was examined by a field emission scanning electron microscopy (FESEM, JEOL JSM-6700) at 5 kV. Prior to imaging, the samples were dispersed onto carbon sticky tabs and coated with gold for 80 seconds using a sputter coater (Cressington 208HR, Watford, UK).
- FESEM field emission scanning electron microscopy
- the particle size distribution of the spray-dried powders was determined by laser diffraction on the Malvern Mastersizer 2000 (Malvern Instruments, UK) using the Scirocco dry dispersion unit.
- the powders were dispersed in triplicates at 3 bars of pressure using refractive indices (RI) of 1.575 for SD-COL and SD-COL/MEM/TGC, 1.639 for SD-MEM, 1.675 for SD-TGC, and 1.613 for SD-RIF, SD-COL/MEM/RIF and SD-COL/TGC/RIF.
- RI refractive indices
- Powder crystallinity of the samples was assessed by powder X-ray diffraction (pXRD) at room temperature using an X-ray diffractometer (D8 Advance; Bruker AXS GmbH, Düsseldorf, Germany). Samples were scanned from 5-45° (2 ⁇ ) with an angular increment of 0.04° and at 1 s per step using Cu K a radiation generated at 35 kV and 40 niA.
- pXRD powder X-ray diffraction
- the specific surface area of the spray-dried powders was determined by a surface area analyzer (Micromeritics ASAP 2420, USA), using nitrogen as the adsorbate gas. Samples were degassed at 25°C for 24 h on a vacuum dryer, prior to the measurements. The specific surface area was then determined by the multipoint Brunauer-Emmett-Teller (BET) gas adsorption/desorption method.
- BET Brunauer-Emmett-Teller
- Approximately 10 mg of powder from each formulation was filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3, Capsugel ® , New Jersey, USA), loaded into an Aerolizer ® inhaler (Novartis Pharmaceuticals, Basel, Switzerland), pierced and then actuated for 4 s at 60 L/min. Six capsules were fired per experiment, delivering a total dose of 60 mg.
- the flow through the NGI was measured using a calibrated flow meter (TSI Model 4040C, TSI Instrument Ltd., Buckinghamshire, UK), controlled by a high capacity vacuum pump (Model HCP5, Copley Scientific, Nottingham, UK) and a critical flow controller (TPK 2000, Copley Scientific, Nottingham, UK).
- the device, capsule, throat and each part of the NGI were washed separately and thoroughly using ethanol-water co-solvent.
- the solutions were then assayed by high performance liquid chromatography (HPLC) after appropriate sample dilutions were made.
- HPLC high performance liquid chromatography
- Each dispersion test was performed in triplicates to obtain mean values.
- the aerodynamic cut-off diameters of stages 1, 2, 3, 4, 5, 6 and 7 are 8.06, 4.46, 2.82, 1.66, 0.94, 0.55 and 0.34 ⁇ .
- Particles with diameter size less than 0.34 ⁇ were captured on a Micro Orifice Collector (MOC) beyond stage 7.
- MOC Micro Orifice Collector
- Fine particle fraction represents the mass fraction of drug particles smaller than 5 ⁇ in the aerosol cloud (FPD) relative to the total mass recovered and was obtained by interpolation to the cumulative percent undersize at 5 ⁇ . FPF (emitted) was obtained when the FPD was expressed relative to the ED.
- a Zorbax Extend C-18 column (4.6 mm x 150 mm, 3.5 ⁇ ) (Agilent Technologies, CA, USA) was used as the stationary phase for simultaneous assays of meropenem, tigecyline and rifampicin.
- the chromatograph separation was performed using a gradient mobile phase system starting with 95:5 solvent A (95% 50 niM ammonium acetate, pH 6.2-5% acetonitrile): B (5% 50 mM ammonium acetate, pH 6.2- 95% acetonitrile) changed to 50:50 solvent A:B over 10 min then ramped to 5:95 solvent A:B in 1 min.
- a 2-min isocratic hold was followed by a step back to the initial conditions.
- a UV absorbance wavelength of 244 nm was employed for the simultaneous detection of meropenem, tigecyline and rifampicin at retention times of 1.7 and 5.7 and 10.6 min, respectively.
- In vitro antimicrobial activity of the spray-dried powders was determined quantitatively via time-kill studies. Overnight cultures of the test organism was diluted in Mueller-Hinton broth (MHB) to give a starting bacterial density of approximately 5 x 10 5 CFU/ml. Spray-dried powders were added to the cultures such that the final concentrations were at 1 x MIC. The cultures were then incubated at 37°C with shaking. Bacterial cell counts were estimated at time 0 and 24 hr.
- a synergistic result was defined as a ⁇ 2 logio decrease in colony count after 24 h by the combination compared to the most active single agent, and additivity as a 1 to ⁇ 2 logio decrease in colony count after 24 h by the combination compared to the most active single agent, and indifference as a ⁇ 1 logio increase or decrease in colony count after 24 h by the combination compared with that by the most active single agent.
- FIG. 1 The schematic diagram of figure 1 illustrates the different mechanisms of action in the representative ternary compositions of the present invention.
- the commercial and conventional antibiotic dry powder inhaler formulations included Novartis ® TIP (Tobramycin Inhaled Powder) and Forest Laboratories ® Colobreathe (Colistin Inhaled Powder).
- the antibiotic combinations described in table 3, were prepared by co- spray drying the ternary system containing colistin sulphate and two other antibiotics (tigecycline, rifampicin or meropenem trihydrate) and were prepared in the weight ratios illustrated in table 4 using the Nano Spray Dryer B-90.
- Table 4 illustrates that the antibiotic combinations are shown to be therapeutically effective against multi-drug resistant Pseudomonas aeruginosa, and specifically a synergistic effect was exhibited by the antibiotic combinations.
- COL colistin
- MEM meropenem
- TGC tigecycline
- RIF rifampicin
- GEN gentamicin.
- the ternary dry powder compositions (Figure 2) consisted of respirable- sized particles (dso ⁇ 3 ⁇ ) capable of achieving high fine particle fractions (FPF) (out of the total dose) of approximately 52-69% and emitted fine particle fractions (FPF(emitted)) of approximately 58-73% (See Table 5 and Table 6). [Table 5]
- Tables 5 and 6 show that the composition of the present invention when formulated as a multi-component particle, are able to achieve the 'same particle size' for each drug (i.e. 3 drugs in a single entity), which leads to more uniform drug deposition for each drug, with advantageous implications in terms of therapeutic efficacy.
- a concomitant and uniform in vitro deposition profile is achieved for the antibiotic combinations across all impaction stages when dispersed at 60 L/min.
- the time-kill assay showed a synergism, > -21ogio change, against resistant Pseudomonas aeruginosa for the three ternary combinations in their co-spray dried form, see Table 4.
- the three ternary combinations are also shown to be effective (i.e. additive or indifferent interactions) against resistant A. baumannii, K. pneumoniae and E. coli.
- SD-COL/TGC/RIF exhibited a favourable 'additive' interaction against multi-drug resistant K. pneumonia and E. coli, see Table 7.
- synergy is defined as a ⁇ 2 logio decrease in colony count after 24 h by the combination compared to the most active single agent, additivity as a 1 to ⁇ 2 logio decrease in colony count after 24 h by the combination compared to the most active single agent and indifference as a ⁇ 1 logio increase or decrease in colony count after 24 h by the combination compared with that by the most active single agent.
- the ternary spray-dried combination powders presented broad diffused diffraction patterns which are characteristic of amorphous materials (similar to their spray-dried individual species), as shown in figure 7. In this regard, it will be appreciated that spray dried powders are typically amorphous.
- compositions of the present invention prevent the emergence of bacterial drug resistance as the simultaneous development of resistance towards multiple drug classes is remote; and secondly from a patient management standpoint, combinations comprising colistin have the potential to reduce colistin toxicity by allowing a lowered therapeutic dose. This is achieved via a synergistic or additive interaction of colistin with its partner antibiotics.
- inhaled delivery of colistin combinations is shown to be effective in eradicating multi-drug resistant (MDR) pathogens as it directly targets the foci of infection.
- MDR multi-drug resistant
- a dry powder inhaler (DPI) formulation is superior over the other aerosol delivery modes (for example, a nebuliser or metered dose inhaler (MDI) in terms of stability, delivery efficiency, portability, ease-of-use and the avoidance of undesired precipitation in solutions.
- DPI dry powder inhaler
- MDI metered dose inhaler
- Rifampicin is a bactericidal antibiotic drug of the ansamycin group that has been used to prevent and treat tuberculosis and other infections, but has very limited use in monotherapy that may be due to the rapid emergence of resistance.
- Meropenem is a member of the carbapenem class of antibiotics that is active against a broad spectrum of Gram-positive and Gram- negative pathogens, including the beta-lactamase producers.
- Tigecycline had been approved by the Food and Drug Administration (FDA) in 2009 for the treatment of community-acquired pneumonia, and was considered a useful alternative against carbapenem-resistant bacteria.
- FDA Food and Drug Administration
- the similarity in surface morphologies of both SD-COL/MEM/RIF and SD-COL/TGC/RIF to SD-RIF may be due to the dominance of rifampicin in the spray- dried ternary combination particles, which resulted in its prevailing influence on their particle morphologies.
- the specific surface areas of the ternary spray-dried formulations containing rifampicin i.e. SD-COL/MEM/RIF and SD-COL/TGC/RIF
- the rifampicin-void spray-dried formulation i.e. SD-COL/MEM/TGC
- SD- COL/MEM/TGC, SD-COL/MEM/RIF and SD-COL/TGC/RIF) were tested against different MDR pathogenic respiratory bacteria and summarized in Tables 4 and 7. In essence, the formulations were all capable of eradicating resistant bacteria.
- SD- COL/MEM/RIF and SD-COL/MEM/TGC could not only eliminate all four species of carbapenem-resistant bacteria, but also elucidate a synergistic response for the MDR Pseudomonas aeruginosa isolate.
- SD-COL/TGC/RIF non-carbapenem (MEM)-containing combination
- MEM non-carbapenem
- SD -COL/TGC/RIF over SD-COL/MEM/RIF and SD- COL/MEM/TGC
- colistin tigecycline and rifampicin's distinct killing mechanisms which targeted different functions of the bacterial cell (Table 3 and Figure 1).
- Bactericidal colistin is a cationic antibiotic that binds to the anionic lipopoly saccharide (LPS) of Gram-negative bacteria's membrane, leading to a disruption of the membrane permeability, leakage of intracellular content and hence cell death.
- LPS anionic lipopoly saccharide
- Perturbation of the bacterial cellular membrane integrity by colistin may in turn favour the uptake of tigecycline and rifampicin to effect a 'collaborative' synergistic interaction.
- Bactericidal rifampicin's mechanism of action is based on its ability to specifically bind and inhibit the bacterial DNA- dependent RNA polymerase.
- bacteriostatic tigecycline works by binding to the 30S subunit of the bacterial ribosome, thus inhibiting peptide elongation and subsequently, disrupting protein synthesis.
- the advantage of the present invention and combination of antibiotics lies in the potential for 'rotational therapy' (i.e. treatment rotated between the three different-member combinations). Recalcitrant bacterial infections that require prolonged antibiotic treatment could benefit from such a therapy while enjoying the reduced risk of antimicrobial resistance. With three unique combinations involving three different complementary antibiotics, the possibility of a bacterium developing resistance to all the antibiotics and combinations simultaneously would hence be very far remote. As such, the present invention and results demonstrated herein provide a 'toolbox' of DPI compositions (for example, COL/TGC/RIF, COL/MEM/RIF and COL/MEM/TGC) to successfully fight against respiratory 'superbugs' .
- DPI compositions for example, COL/TGC/RIF, COL/MEM/RIF and COL/MEM/TGC
- the benefits of co-delivery include the potential for synergy which helps to further lower the toxic drug dose and the associated side effects (i.e. colistin), ameliorating the performance of a poorer-performing species (i.e. meropenem), the life-span extension of 'expiring/redundant' antibiotics (i.e. meropenem, rifampicin and tigecycline) and the opportunity to mount a collaborative and concerted mode of attack on bacteria (i.e. COL/TGC/RIF).
- the DPI compositions do not require a bulky nebuliser, are easier and quicker to use, and provide much better formulation stability as it is formulated as a powder. Furthermore, the DPI compositions are capable of a high FPF of -52-69%, much higher than that achieved via the traditional nebuliser (-10%).
- compositions of the present invention and the therapeutic effect of the antibiotic combinations was shown to be advantageous.
- the compositions were also capable of killing resistant A. baumannii, K. pneumonia and E. coli bacteria with either an indifferent or additive interaction. Therefore, the development of the compositions disclosed herein is indeed a novel and timely intervention in the fight against multi-resistant pathogenic respiratory bacteria.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present disclosure provides dry powder antibiotic compositions that are effective in the treatment of bacterial infections and associated conditions. Moreover, the present disclosure provides dry powder antibiotic compositions for the treatment of bacterial infections, by multi-drug resistant bacteria, resulting in the subsequent reduction in the prevalent rates of drug resistance.
Description
Antibiotic Compositions for Treating Bacterial
Infections
Cross-Reference to Related Applications
This application claims the benefit of priority of Singapore provisional application No. 10201404407X filed 25 July 2014, the contents of it being hereby incorporated by reference in its entirety for all purposes.
Technical Field
The present invention generally relates to the fields of microbiology, biotechnology, and inhalation aerosols. More specifically, the present invention relates to dry powder compositions for the treatment of bacterial infections, such as multi-drug resistant bacterial infections.
Background Art
Respiratory lung infections due to multidrug resistant pathogens are increasing worldwide. Their multidrug resistance profile makes currently available therapeutic options extremely limited. Some of these pathogens include methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant Streptococcus pneumoniae, and vancomycin-resistant enterococci (VRE) among the Gram-positive bacteria; and multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacteriaceae (including Klebsiella pneumoniae and Escherichia coli), among the Gram-negative bacteria.
In view of the rising bacterial resistance rates worldwide, there is an anticipated demand for novel antibiotic compositions to broaden the antimicrobial spectrum, improve the efficacy,
prevent the emergence/re-emergence of resistant bacteria, and lower the dose of the individual drugs to reduce the side effects as well as the treatment costs.
The development of resistance to antibiotics is well -documented for both Gram-negative bacteria and Gram-positive bacteria, which has implications in the ability to treat pulmonary infections and respiratory diseases that afflict millions of people across the world leading to suffering, economic loss and premature death. In particular, Gram-negative bacteria are more resistant to antibiotics than Gram-positive bacteria due to the presence of a second outer membrane, which provides an efficient barrier to both hydrophilic and hydrophobic compounds. Consequently, Gram-negative bacterial infections are typically more problematic to treat in view of the fewer classes of antibiotics available for effective treatment.
As carbapenems (for example, imipenem, meropenem and doripenem) possess broad- spectrum activity against many Gram-negative bacteria they remain the 'final-line' drug of choice for extended- spectrum, β-lactamase-producing organisms. However, the increasing prevalence of carbapenem-resistant and carbapenemase-producing organisms is jeopardizing the efficacy of carbapenems (carbapenem-resistant bacteria are "superbugs", exhibiting broad resistance to many other antibiotic classes, often leaving the infection untreatable). Hence, seeking alternative treatment regimens has become a pressing issue.
Currently, colistin (a 50-year old polymyxin class of antibiotics), is undergoing a period of revival, and is favored as a 'last line' therapeutic against these hard to treat multidrug- resistant bacteria, such as P. aeruginosa, A. baumannii and K. pneumoniae. Unfortunately, in recent years, sporadic reports of colistin-resistant strains have started emerging from various parts of the world (for example, Singapore, Greece, Israel and South Korea).
Combination regimens are therefore attractive alternative strategies to overcoming these rising rates of drug resistance in the dearth of newer antibiotics. Inhaled delivery of these combination compounds are useful in eradicating these pathogens more effectively due to direct lung targeting at high minimum inhibitory concentrations (MICs). The simultaneous use of multiple classes of antibiotics is also useful in protecting against the re-emergence of drug resistant bacteria.
As such, there is a need in the art for antibiotic compositions that are effective in the treatment of infections by multi-drug resistant bacteria, and the subsequent reduction in the prevalent rates of drug resistance.
Summary of invention
In one embodiment, there is provided a dry powder composition comprising: a polymyxin antibiotic; and at least one further antibiotic selected from the group consisting of an aminoglycoside, an ansamycin, a carbacephem, a carbapenem, a cephalosporin, a glycopeptide, a lincosamide, a lipopeptide, a macrolide, a monobactam, a nitrofuran, a oxazolidonone, a penicillin, a polypeptide, a quinolone, a sulfonamide, a tetracycline, a chloramphenicol, a phosphonic acid antibiotic and a mycobacteria antibiotic.
In another embodiment, there is provided the use of a dry powder composition as described herein in the manufacture of a medicament for treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium. In another embodiment, there is provided the use of a dry powder composition as described herein in the manufacture of a medicament for treating a respiratory system infection by a bacterium.
In another embodiment, there is provided the use of a dry powder composition as described herein in the manufacture of a medicament for treating a pulmonary disease or condition.
Brief description of drawings
The invention will be better understood with reference to the detailed description when considered in conjunction with the non-limiting examples and the accompanying drawings, in which: Fig.l shows the different mechanisms of action of the antibiotic combinations of the present invention.
Fig. 2 shows the Field Emission Scanning Electron Microscopy (FESEM) images of the spray dried powders of a) SD-COL/TGC/RIF; b) SD-COL/MEM/TGC; c) SD- COL/MEM/RIF; d) SD-COL; e) SD-TGC; f) SD-MEM and g) SD-RIF. COL = colistin; MEM = meropenem; TGC = tigecycline; RIF = rifampicin; GEN = gentamicin and SD = spray dried.
Fig. 3 shows In vitro deposition of the co-spray dried ternary formulation SD-COL/TGC/RIF at 60 L/min of airflow. NGI = Next Generation Impactor; Stages 1-7 = impactor stages, with the corresponding aerodynamic cutoff diameter in parentheses; MOC = NGI micro-orifice collector. Fig. 4 shows In vitro deposition of the co-spray dried ternary formulation SD- COL/MEM/TGC at 60 L/min of airflow. NGI = Next Generation Impactor; Stages 1-7 = impactor stages, with the corresponding aerodynamic cutoff diameter in parentheses; MOC = NGI micro-orifice collector.
Fig. 5 shows In vitro deposition of the co-spray dried ternary formulation SD- COL/MEM/RIF at 60 L/min of airflow. NGI = Next Generation Impactor; Stages 1-7 = impactor stages, with the corresponding aerodynamic cutoff diameter in parentheses; MOC = NGI micro-orifice collector.
Fig. 6 shows In vitro deposition of the spray dried individual species at 60 L/min of airflow, (a) SD-COL, (b) SD-MEM, (c) SD-TGC, (d) SD-RIF. NGI = Next Generation Impactor; Stages 1-7 = impactor stages, with the corresponding aerodynamic cutoff diameter in parentheses; MOC = NGI micro-orifice collector.
Fig. 7 shows the X-Ray diffraction patterns of SD-COL/MEM/RIF, SD-COL/MEM/TGC, SD-COL/TGC/RIF and their spray-dried individuals.
Definitions
The following are some definitions that may be helpful in understanding the description of the present invention. These are intended as general definitions and should in no way limit
the scope of the present invention to those terms alone, but are put forth for a better understanding of the following description.
As used herein, the term "composition" in the context of the present invention refers to a combination of antibiotics optionally containing other components, such as carriers, excipients, diluents, isotonic solutions, buffers and the like. The term "formulation" means a specific composition formulated for specific use, such as for aerosolization of an antibiotic in either the dry powdered, solution or suspension form.
As used herein, the term "antibiotic" refers to a natural or synthetic substance that has the capacity to inhibit the growth of, or to kill other microorganisms. As used herein, the term "microorganism" refers to prokaryotic and eukaryotic cells, which grow as single cells, or when growing in association with other cells, do not form organs (for examples microorganisms include bacteria, yeast, molds, and fungi).
As used herein, the language "pharmaceutically acceptable carrier" is intended to include solvents, dispersion media, coatings, anti-bacterial and anti-fungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the compound, use thereof in the therapeutic compositions and methods of treatment and prophylaxis is contemplated. Supplementary active compounds may also be incorporated into the compositions according to the present invention.
As used herein, the term "treatment" refers to any and all uses which remedy an infection, disease state or symptoms, prevent the establishment of disease, or otherwise prevent, hinder, retard, or reverse the progression of an infection or disease or other undesirable symptoms in any way whatsoever. The terms "treat," or "treating," refers to administering a medicament for prophylactic and/or therapeutic purposes. The term "prophylactic treatment" refers to treating a subject who is not yet infected, but who is susceptible to, or otherwise at risk of, a particular infection such that there is a reduced onset of infection. Treatment may eliminate the infection, or it may reduce the bacterial load in the tissues that results in improvements measured by a subject's symptoms or measures of lung function.
As used herein, the term "bacterial infection" refers to the undesired proliferation or presence of invasion of bacteria in a host organism or subject. This includes the excessive growth of bacteria that are normally present in or on the body of a mammal or other organisms. More generally, a bacterial infection can be any situation in which the presence of a bacteria population(s) is damaging to a subject. Thus, a bacterial infection exists when excessive numbers of a bacterial population are present in or on a subject's body, or when the effects of the presence of a bacterial population(s) is damaging the cells or other tissue of a subject.
As used herein, the term "drug resistant" when used in reference to bacterium refers to a bacterium that is resistant to the antimicrobial activity of a drug, such as an antibiotic. Drug resistance may also be referred to as antibiotic resistance. In some cases, a bacterium that is generally susceptible to a particular antibiotic can develop resistance to the antibiotic, thereby becoming a drug resistant bacterium. A "multi-drug resistant" bacterium is one that is resistant to more than one drug having antimicrobial activity. One skilled in the art can readily determine if a microbe is drug resistant using routine laboratory techniques that determine the susceptibility or resistance of a bacterium to a drug or antibiotic.
As used herein, the term "synergistic effect" refers to a larger therapeutic effect of the combined antibiotics of the formulations disclosed in comparison to the effect predicted from the sum of each antibiotic alone.
Detailed Description
The present invention provides a novel antibiotic composition for the treatment of bacterial infections, respiratory diseases and pulmonary infections. More particularly, the present invention and antibiotic composition represents a novel and timely intervention in the fight against multi-resistant bacteria. I. Antibiotic Composition
Antibiotics that may be used in the present invention include, but are not limited to broad- spectrum antibiotics (for example, tetracyclines); medium- spectrum antibiotics (for example, bacitracin, erythromycins, penicillin, cephalosporins and streptomycins); and narrow
spectrum antibiotics (for example, antibiotics that are effective against only a few species of bacteria, for example, polymyxins).
In particular, the antibiotics that may be used in the present invention are selected from an antibiotic family or class including but not limited to aminoglycoside, ansamycin, carbacephem, carbapenem, cephalosporin, glycopeptide antibiotic, lincosamide, lipopeptide, macrolide, monobactam, nitrofuran, oxazolidonone, penicillin, polymyxin, polypeptide antibiotic, quinolone, sulfonamide, tetracycline, chloramphenicol, phosphonic acid antibiotic and mycobacteria antibiotic. The antibiotic families described herein and their specific subclasses of antibiotics are well defined and known in the art by the skilled artisan. Nevertheless, the following non-limiting examples of specific antibiotics that are categorized under each family are defined in the below Table 1.
[Table 1]
Antibiotic Family/Class Specific Antibiotics
aminoglycoside neomycin, amikacin, kanamycin, streptomycin and tobramycin ansamycin Rifamycin, rifaximin, rifapentine, rifabutin, rifampicin, naphthomycins, geldanamycin, ansamitocin and streptovaricins carbacephem A class of synthetic antibiotics, based on the structure of cephalosporin, a cephem. Carbacephems are similar to cephems, but with a carbon substituted for the sulfur, for example Loracarbef
carbapenem Imipenem, doripenem, ertapenem and meropenem
cephalosporin cephalexin, cefadroxil, cefdinir, cefoxitin, cefaclor, ceftaroline and cefixime
glycopeptide A class of drugs of microbial origin that are composed of glycosylated cyclic or polycyclic nonribosomal peptides, and may include but not limited to vancomycin, teicoplanin, telavancin, ramoplanin and decaplanin
lincosamide clindamycin and lincomycin
lipopeptide daptomycin
macrolide azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, troleandomycin, telithromycin, spiramycin
monobactam aztreonam
nitrofuran furazolidone, nitrofurantoin
oxazolidonone Linezolid, posizolid, radezolid, torezolid
penicillin amoxicillin, ampicillin, azlocillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, methicillin, nafcillin, oxacillin, penicillin G, penicillin V, piperacillin, temocillin, ticarcillin
polymyxin colistin, polymyxin B
polypeptide Bacitracin
Quinolone Ciprofloxacin, Nadifloxacin, Levofloxacin, Moxifloxacin,
Sparfloxacin and Gatifloxacin
Sulfonamide co-trimoxazole, dapsone, silver sulfadiazine, mafenide, sulfacetamide.
tetracycline doxycycline, minocycline, tigecycline, demeclocycline, oxytetracycline, tetracycline analogues
Chloramphenicol chloramphenicol.
phosphonic acid fosfomycin
Anti-mycobacterial streptomycin, clofazimine, capreomycin, dapsone, D- cycloserine, ethambutol, ethionamide, isoniazid, pyrazinamide, rifampin, rifabutin, rifapentine
As it will be appreciated, analogues or variants of the antibiotics listed in Table 1 may be used in the present invention. These antibiotics may be referred to as "functional analogues or variants" that maintain the antibiotic activity as compared to the reference antibiotic. The functional analogue or variant antibiotics may be found in nature or be an engineered mutant thereof. Moreover, the antibiotic activity of the analogues or variants may be readily determined by well-known methods and techniques in the art.
In accordance with the present invention, two or more antibiotics may be used in combination. In another embodiment, three or more antibiotics may be used in combination, and preferably three antibiotics may be used in combination. A combination of three antibiotics may be referred to as a ternary drug combination.
In this regard, the combination of antibiotics is formulated into a composition.
Thus, the present invention provides a composition comprising at least two or at least three antibiotics selected from the group consisting a polymyxin, an aminoglycoside, an ansamycin, a carbacephem, a carbapenem, a cephalosporin, a glycopeptide, a lincosamide, a lipopeptide, a macrolide, a monobactam, a nitrofuran, a oxazolidonone, a penicillin, a polypeptide, a quinolone, a sulfonamide, a tetracycline, a chloramphenicol, a phosphonic acid antibiotic and a mycobacteria antibiotic.
In one embodiment, an antibiotic comprised in the composition is a polymyxin. Accordingly, in one embodiment, the composition comprises a polymyxin antibiotic; and at least one further antibiotic selected from the group consisting of an aminoglycoside, an ansamycin, a carbacephem, a carbapenem, a cephalosporin, a glycopeptide, a lincosamide, a lipopeptide, a macrolide, a monobactam, a nitrofuran, a oxazolidonone, a penicillin, a polypeptide, a quinolone, a sulfonamide, a tetracycline, a chloramphenicol, a phosphonic acid antibiotic and a mycobacteria antibiotic.
In one embodiment, the polymyxin is colistin (polymyxin E). In one embodiment, the colistin is colistin sulphate.
In another embodiment, the at least one further antibiotic is selected from the group consisting of a carbapenem, an ansamycin and a tetracycline.
In one embodiment, the carbapenem is selected from the group consisting of ertapenem, doripenem, imipenem and meropenem. In a preferred embodiment, the carbapenem is meropenem.
In one embodiment, the ansamycin is rifampicin.
In one embodiment, the tetracycline is selected from the group consisting of demeclocycline, doxycycline, minocycline, oxytetracycline and tetracycline analogues. In a preferred embodiment, the tetracycline is tigecycline.
In one embodiment, the composition comprises three antibiotics. As such, in one embodiment, the composition comprises a polymyxin antibiotic, an ansamycin antibiotic and
a tetracycline antibiotic. In a preferred embodiment, the composition comprises colistin, tigecycline and rifampicin.
In another embodiment, the composition comprises a polymyxin antibiotic, a tetracycline antibiotic and a carbapenem antibiotic. In a preferred embodiment, the composition comprises colistin, meropenem and tigecycline.
In another embodiment, the composition comprises a polymyxin antibiotic, an ansamycin antibiotic and a carbapenem antibiotic. In a preferred embodiment, the composition comprises colistin, meropenem and rifampicin.
II. Additional Components The composition may be formulated with one or more components. The selection of the one or more components may be readily chosen by the skilled artisan based upon the formulation of the composition and route of administration. The suitability of the one or more components may be readily known by those skilled in the art or may be determined using well-known techniques. The one or more components may comprise excipients, antibiotics, a pharmaceutically acceptable carrier, a mucolytic agent, an anti-inflammatory agent, or pharmaceutically active ingredients.
For example, if the composition is formulated as a dry powder formulation that is to be administered using a dry powder inhaler, the composition may comprise one or more components which are commonly used in the preparation of a dry powder formulation, such as an excipient. Thus, in one embodiment the one or more components may comprise an excipient. In general, excipients are used to enhance the physical or chemical stability of the active ingredient, and its mechanical properties, and/or its pharmaceutical properties, such as dissolution and permeation. In dry powder formulations, excipients function as carrier particles to reduce drug cohesiveness by occupying the high-energy sites of the drug particles. Examples of carrier particles may include sugars or sugar alcohols such as mannitol, lactose, glucose, sorbitol, trehalose, raffinose or dextrose. Usually, no more than a few milligrams of a drug need be delivered, and excipients provide bulk, which improves handling, dispensing, and metering of the drug. Other excipients may be phospholipids, such as phosphatidylcholine and cholesterol; lubricants that reduce drug cohesion and adhesion,
such as leucine, magnesium stearate, sodium stearate, polyethylene glycol; polymers that act as drug release modifiers or formulation stability enhancers, such as chitosan, polyvinyl alcohol, polylactic-co-glycolic acid; sugar polymers, such as dextran, dextrin; or stabilizers, such as tocopherol, cyclodextrins, polymers, albumins, antioxidants, surfactants and salts. Excipients may make up over 99% of the dry powder inhaler formulation by weight. Physiochemical properties of the excipient such as size and morphology may affect the performance of the dry powder formulation. The adhesive forces of the formulation may also be considered, wherein inadequate separation of the active ingredient and carrier is the main reason for deposition problems. Thus, the excipient may be modified before combining it with the compositions of the present invention. It should also be appreciated that excipients are not always required.
In another embodiment, the one or more components may comprise a mucolytic agent and/or an anti-inflammatory agent. A mucolytic agent helps to loosen and clear mucus from an airway that has been infected by a bacteria or virus. The mucolytic agent may include a lysozyme, ambroxol hydrochloride, sodium chloride, N-acetylcysteine, or mannitol. An antiinflammatory agent reduces infection severity and may include a steroid or a non-steroidal anti-inflammatory drug, such as aspirin, ibuprofen, naproxen. It is also possible to use more than one mucolytic agent or anti-inflammatory agent in the composition.
In another embodiment, the one or more components may comprise pharmaceutically active ingredients. For example, the formulation may comprise a pharmaceutical composition used for treating lung cancer, steroids (for example, budesonide), beta-2-agonists (for example, salbutamol sulphate), anticholinergics (for example, ipratropium bromide), mucolytic agents (for example, lysozyme, ambroxol hydrochloride), substances added to improve wound healing (for example, heparin), anti-histimine (for example, cetrizine hydrochloride) or decongestants (for example, pseudoephedrine).
In another embodiment, the one or more components may comprise anti-fungal agents to target mixed pathogen populations. The anti-fungal agents may include but are not limited to polyene anti-fungal agents (for example, Amphotericin B, Nystatin or Pimaricin), azole anti-
fungal agents (for example, Posaconazole, Voriconazole, Fluconazole or Itraconazole), or Echinocandin anti-fungal agents (for example, Caspofungin, Micafungin or Anidulafungin).
In another embodiment, the one or more components may comprise anti-cancer drugs for concurrent cancer, and bacterial or mixed infection therapy, whereby a weakened immune system and hence an increased risk for pathogenic infections is a common occurrence during the cancer treatment. The anti-cancer drugs may include but are not limited to Cisplatin, Paclitaxel, Doxurubicin, Methotrexate, Carboplatin or Gemcitabine. In another embodiment, the one or more components may comprise a pharmaceutically acceptable carrier. The carrier may include, for example, one or more of the following: suspension aids, desiccants, diluents, stabilizers, glidants, binders, fillers and bulking agents, and the like. The filler material and bulking agents may comprise about 10 to 95% of the composition. In a preferred embodiment, the filler(s) will make up about 60 to 85% of the composition. Filler material can include any inert pharmaceutical bulking agent or material. Preferably, microcrystalline cellulose is utilized. Also highly efficacious is mannitol as a filler/bulking agent. Silicon dioxide also has excellent bulking properties. It is desirable that a combination of microcrystalline cellulose, mannitol and silicon dioxide be provided.
As such, in one embodiment the composition disclosed herein may comprise one or more components selected from the group consisting of excipients, antibiotics, a pharmaceutically acceptable carrier, a mucolytic agent, an anti-inflammatory agent, and pharmaceutically active ingredients. In one embodiment, the one or more components is suitable for oral or nasal administration.
III. Dry Powder Composition The compositions described herein may be prepared in the form of a dry powder. Accordingly, in one embodiment the composition described herein is a dry powder composition.
The composition described herein may be milled, precipitated, spray dried or otherwise processed to particle sizes between about 1 and 5μιη in preparing the dry powder composition. In particular, the composition described herein may be prepared to a powder
having particles with volume median diameters (d5o) ranging from 1-10 μιτι, more preferably 0.1-7 μιη, 0.1-5 μιη or 0.5-5 μιτι, by media milling, jet milling, spray drying or particle precipitation techniques that are readily known in the art. As such, in one embodiment the volume median diameter (d5o) of the particles in the dry powder composition is in the range of 0.5-10 μιη, and preferably in the range of 1-5 μιη. In one embodiment, the dry powder composition is prepared by spray-drying. The technique of spray-drying uses methods conventionally known in the art and involves spraying a fine mist of the composition through a nozzle and into a hot vapor stream. The particles are dried in the process and are then collected. It will be readily appreciated by the skilled artisan that techniques suitable for preparation of dry powders and any and all improvements thereof are intended to be within the scope of the invention.
As such, in one embodiment, the present invention provides a dry powder composition comprising a polymyxin antibiotic; and at least one further antibiotic selected from the group consisting of an aminoglycoside, an ansamycin, a carbacephem, a carbapenem, a cephalosporin, a glycopeptide, a lincosamide, a lipopeptide, a macrolide, a monobactam, a nitrofuran, a oxazolidonone, a penicillin, a polypeptide, a quinolone, a sulfonamide, a tetracycline, a chloramphenicol, a phosphonic acid antibiotic and a mycobacteria antibiotic.
Any effective weight ratio of the antibiotics in the composition may be used. The weight ratio of the antibiotics in the dry powder composition will depend on the particular dosing regimen, and how much of each of the particular antibiotics is to be included in the final dose.
In one embodiment, the weight ratio of the polymyxin antibiotic to the at least one further antibiotic may be in the range from about 1:5 to about 5: 1; or from about 1: 1 to about 2:1, preferably from about 1:4 to about 4: 1, more preferably from about 1:3 to about 3: 1. In one embodiment, the weight ratio of the polymyxin antibiotic to the at least one further antibiotic may be 5:4 or 5: 12.
In another embodiment, the dry powder composition comprises three antibiotics. In one embodiment, the dry powder composition comprises a polymyxin antibiotic, an ansamycin antibiotic and a tetracycline antibiotic in a weight ratio of about 5:4: 12. In one embodiment,
the dry powder composition comprises colistin, tigecycline and rifampicin in a weight ratio of about 5:4: 12.
In another embodiment, the dry powder composition comprises a polymyxin antibiotic, a tetracycline antibiotic and a carbapenem antibiotic in a weight ratio of about 5:4:4. In a preferred embodiment, the dry powder composition comprises colistin, meropenem and tigecycline in a weight ratio of about 5:4:4.
In another embodiment, the dry powder composition comprises a polymyxin antibiotic, an ansamycin antibiotic and a carbapenem antibiotic in a weight ratio of about 5:4: 12. In a preferred embodiment, the dry powder composition comprises colistin, meropenem and rifampicin in a weight ratio of about 5:4: 12.
In one embodiment, the dry powder compositions of the present invention and antibiotic combinations may exhibit a therapeutic effect indifferent, additive or larger than the effect predicted from the sum of each antibiotic alone. In one embodiment, the dry powder composition described herein may exhibit a therapeutic effect larger than the effect predicted from the sum of each antibiotic alone. In one embodiment, the dry powder composition described herein exhibits a synergistic effect.
IV. Administration of Dry Powder Composition
Convenient modes of administration of the dry powder composition described herein may include injection (for example subcutaneous or intravenous administration), oral administration, inhalation, or transdermal administration. Depending on the route of administration, the dry powder composition may be coated with a material for protection from the action of enzymes, acids and other natural conditions which may inactivate the therapeutic activity of the compound. As such, the administration of the dry powder compositions disclosed herein may be via any of the accepted modes of administration including, but not limited to nasal, oral, transdermal, subcutaneous or intravenous. These modes of administration refer to the conventional routes of administration and are readily understood by the skilled artisan based upon the intended use and composition.
In one embodiment, the dry powder composition is formulated to be administered nasally, orally, transdermally, subcutaneously or intravenously. In one embodiment, the dry powder composition is formulated to be administered by an inhaler, a syringe, an implantable device, a medically inserted device or a biomaterial. In particular, the dry powder composition may be reconstituted as an injectable suspension for administration by injection. The implantable device and medically inserted device or biomaterial are those readily known to the skilled artisan for delivery of antibiotics. For example, a medically inserted device may comprise a catheter; and an implantable device or biomaterial may comprise a prosthesis, an artificial heart valve, a breast implant or a dental implant. In particular, the dry powder compositions described herein may be suitably formulated into solid, semi-solid, liquid and aerosol dosage forms, such as liquids, suspensions, complexations, liposomes or particulates.
In one embodiment, the dry powder compositions may, for example, be prepared as a liquid by dissolving, dispersing, the composition described herein in a carrier (e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol or the like) to form a solution or suspension. Solutions to be aerosolized can be prepared in conventional forms, either as liquid solutions or suspensions, as emulsions, or in solid forms suitable for dissolution or suspension in liquid prior to aerosol production and inhalation. In one embodiment, the dry powder composition is administered by injection. In the case of injectable solutions prepared from the dry powder compositions, the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
In another embodiment, the dry powder composition described herein is formulated to be inhaled by the subject either through nasal or oral administration for delivery to a subject's respiratory tract. For administration to the respiratory airways of a subject, the inhalation of the dry powder composition described herein may be via the mouth and throat.
As such, in one embodiment the compositions described herein are dry powder inhalation compositions. In one embodiment, the dry powder composition does not require any further handling such as diluting of the dry powder, and thus is practical and convenient. As such, it is a preferred embodiment that the compositions described herein be prepared as a dry
powder inhalation composition with the advantage of being both practical and convenient because it does not require dilution or other handling, it has an extended shelf-life and storage stability and the dry powder inhalation delivery devices are portable and do not require an air compressor needed by aerosol nebulizers. In particular, the administration of the dry powder inhalation composition to the upper airways may be avoided in favor of the middle and lower airways of the respiratory tract. In one embodiment, the dry powder inhalation compositions may be endobronchial^ administered for efficacious delivery of the antibiotic composition into the endobronchial space. In this regard, particles of the dry powder compositions having an aerodynamic diameter of greater than about 5 microns generally do not reach the lung; instead, they tend to impact the back of the throat and are swallowed and possibly orally absorbed. Particles having diameters of about 2 to about 5 microns are small enough to reach the upper- to mid- pulmonary region (conducting airways), but are too large to reach the alveoli. Smaller particles, i.e., about 0.5 to about 2 microns, are capable of reaching the alveolar region. Particles having diameters smaller than about 0.5 microns can also be deposited in the alveolar region by sedimentation, although very small particles may be exhaled.
A dry powder inhalation composition has potency, on a mass basis, which allows delivery of the compositions described herein through the use of a dry powder inhaler. In this regard, the dry powder composition may be administered by devices that are sufficiently small, fully portable and do not require, for example, an air compressor which is needed for a jet nebulizer. Additionally, the dry powder composition has a longer shelf life than liquid compositions for aerosolization.
In one embodiment, the dry powder inhalation composition described herein is administered via an inhalation device. In particular, the dry powder composition may be administered by dry powder inhalers, nebulizers or metered dose inhaler. In relation to the nebulizer and metered dose inhaler the dry powder composition may be reconstituted into a suspension.
In one embodiment, the dry powder inhalation composition described herein is administered via a dry powder inhaler. The dry powder inhaler may be designed for single use or multiple use or as a re-usable or disposable inhaler.
The emitted dose (ED) of the dry powder inhalation composition described herein is the total mass of the antibotics emitted from the inhalation device following actuation. It does not include the material left on the internal or external surfaces of the device, or in the metering system including, for example, the capsule or blister. The dry powder inhaler may disperse the dry powder formulation at a rate between about 30 to about 100 L/min, 30 to about 80 L/min, 30 to about 70 L/min, 40 to about 90 L/min, 30 to about 60 L/min, 40 to about 70 L/min, 50 to about 70 L/min, 30 L/min, 40 L/min, 50 L/min, 60 L/min or 70 L/min. Administration at these rates can achieve a substantially uniform deposition profile across all impaction stages. The fine particle dose (FPD) is the total mass of active agent which is emitted from the device following actuation which is present in an aerodynamic particle size smaller than a defined limit. This limit is generally taken to be 5 μπι if not expressly stated to be an alternative limit, such as 3 μπι, 2 μπι or 4 μπι. The FPD and ED are both measured using an impactor or impinger, such as a twin stage impinger (TSI), multi-stage liquid impinger (MSLI), Andersen Cascade Impactor (ACI) or a Next Generation Impactor (NGI). Each impactor or impinger has a pre-determined aerodynamic particle size collection cut point for each stage. The FPD value is obtained by interpretation of the stage-by- stage active agent recovery quantified by a validated quantitative wet chemical assay where either a simple stage cut is used to determine FPD or a more complex mathematical interpolation of the stage-by-stage deposition is used.
The fine particle fraction (FPF) represents the mass fraction of drug particles smaller than 5 μηι in the aerosol cloud (FPD) relative to the total mass recovered and may be obtained by interpolation to the cumulative percent under size at 5 μιη. FPF (emitted) may be obtained when the FPD is expressed relative to the ED. As such, in one embodiment of the present invention, the dry powder inhalation composition has a fine particle fraction (FPF) of at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, or at least 70%. In one embodiment, the dry powder inhalation composition has a fine particle fraction of at least 50%.
The dry powder compositions described herein may be administered with a frequency of about 1, 2, 3, 4, or more times daily, 1, 2, 3, 4, 5, 6, 7 or more times weekly, 1, 2, 3, 4, 5, 6, 7,
8, 9, 10 or more times monthly. In one embodiment, the compositions are administered twice daily. Single or multiple administrations of the compositions according to the invention may be carried out. One skilled in the art would be able, by routine experimentation, to determine effective, non-toxic dosage levels of the composition of the invention and an administration pattern which would be suitable for treating the diseases and/or infections to which the compositions are applicable. Further, it will be apparent to one of ordinary skill in the art that the optimal course of treatment, such as the number of doses of the compound or composition of the invention given per day for a defined number of days, can be ascertained using convention course of treatment determination tests. V. Treatment of Bacterial Infection
The dry powder compositions described herein may be used to treat bacterial infections in a subject. The subject may be an animal, and in particular a mammal. The term "mammal" is used in its usual biological sense and includes humans, cattle, horses, dogs, and cats, but also includes many other species. In this regard, the bacterial infection may be derived from a bacterium selected from the group consisting of Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonas putida, Stenotrophomonas maltophilia, Aeromonas hydrophilia, Escherichia coli, Citrobacter freundii, Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia alcalifaciens, Providencia rettgeri, Providencia stuartii, Acinetobacter calcoaceticus, Acinetobacter baumannii- calcoaceticus complex, Acinetobacter haemolyticus, Yersinia enter ocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Bordetella pertussis, Bordetella parapertussis, Bordetella bronchiseptica, Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Haemophilus ducreyi, Pasteurella multocida, Pasteurella haemolytica, Helicobacter pylori, Campylobacter fetus, Campylobacter jejuni, Campylobacter coli, Borrelia burgdorferi, Vibrio cholera, Vibrio parahaemolyticus, Legionella pneumophila, Listeria monocytogenes,
Neisseria gonorrhoeae, Neisseria meningitidis, Burkholderia cepacia, Francisella tularensis, Kingella, and Moraxella.
In another embodiment, the bacterium is selected from the group consisting of Bacteroides fragilis, Bacteroides distasonis, Bacteroides 3452A homology group, Bacteroides vulgatus, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii, Bacteroides splanchnicus, Corynebacterium diphtheriae, Corynebacterium ulcerans, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus milleri; Streptococcus (Group G); Streptococcus (Group C/F); Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus intermedius, Staphylococcus hyicus subsp. hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saccharolyticus, Clostridium difficile, Clostridium perfringens, Clostridium tetini, and Clostridium botulinum.
In another embodiment, the bacterium is an acid-fast bacterium. In one embodiment, the lung bacterium is selected from the group consisting of Mycobacterium tuberculosis, and non- tuberculous Mycobacterium including Mycobacterium avium, Mycobacterium intracellular, Mycobacterium abscesses and Mycobacterium leprae.
In one embodiment, the bacterium is a Gram-negative bacterium selected from the group consisting of Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii- calcoaceticus complex and Mycobacterium species.
In one embodiment, the bacterium is a Gram-negative bacterium, a Gram-positive bacterium or an acid-fast bacterium. In another embodiment, the bacterium is a multidrug resistant bacterium.
Thus, in one embodiment the present invention provides the use of a dry powder composition described herein in the manufacture of a medicament for treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium.
A subject may be identified as "infected" or "suspected to be infected" with multidrug resistant bacterium by virtue of the subject having symptoms that are characteristic of a bacterial infection with a bacteria species known to have resistant strains or with a bacteria
that is a member of groups that are known to have resistant strains. Alternatively, the bacteria may be isolated from the subject, cultured and identified as a bacteria species known to have resistant strains or a bacteria that is a member of group that are known to have resistant strains. A subject may be identified as "at risk of infection" with multidrug resistant bacterium by the subject having a wound or a condition or a disease that improves the possibility and occurrence of a bacterial infection, such patients at risk for infection are selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In another embodiment, a subject may be identified as "at risk of infection" with multidrug resistant bacterium if the subject visits or resides in a location known to be, or likely to be, colonized with multidrug resistant bacterium, such as a medical facility where multi-drug resistant Staphylococcus aureus (MDRSA) and multi-drug resistant Pseudomonas species may be present. This embodiment may be considered as a prophylactic treatment of a multidrug resistant bacterial infection.
In this regard, the bacterial infection may be a respiratory system infection such as a pulmonary infection. In one embodiment, the present invention provides the use of a dry powder composition described herein in the manufacture of a medicament for treating a respiratory system infection by a bacterium. In one embodiment, the bacterium is a multidrug resistant bacterium. In one embodiment, the bacterial respiratory system infection is laryngitis, bronchitis, pneumonia, or sinusitis.
In another embodiment, the present invention provides the use of a dry powder composition described herein in the manufacture of a medicament for treating a pulmonary disease or condition. Examples of such disorders can include cystic fibrosis, and chronic obstructive pulmonary disease (COPD), including chronic bronchitis, bronchiectasis and some asthmas. As such, in one embodiment the pulmonary disease or condition is cystic fibrosis, bronchiectasis or chronic obstructive pulmonary disease (COPD).
As it may be appreciated, the dry powder compositions described herein may be applied to a method for treating a bacterial infection in a subject, in particular for treating respiratory system infections. Moreover, the dry powder compositions described herein may be applied
to a method for treating a pulmonary disease or condition. In one such embodiment, this method may be used to administer the dry powder composition to the site of infection. Such a method may reduce systemic exposure and maximizes the amount of dry powder composition to the site of bacterial infection. Accordingly, in one embodiment, the present invention provides a method of treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium, comprising administering to the subject a dry powder composition as described herein.
In another embodiment, there is provided a method of treating a respiratory system infection by a bacterium in a subject, comprising administering to the subject a dry powder composition as described herein. In one embodiment, the bacterium is a multidrug resistant bacterium. In one embodiment, the multidrug resistant bacterium is selected from the group consisting of Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumonia and Escherichia coli. In one embodiment, the bacterial respiratory system infection is laryngitis, bronchitis, pneumonia, or sinusitis.
In another embedment, there is provided a method of treating a pulmonary disease or condition in a subject, comprising administering to the subject a dry powder composition as described herein. In one embodiment, the pulmonary disease or condition is cystic fibrosis, bronchiectasis, or chronic obstructive pulmonary disease (COPD).
The amount of the respective antibiotics in the dry powder compositions to be administered will, of course, be dependent on the subject and disease state being treated, the severity of the affliction, the manner and schedule of administration and the judgment of the prescribing physician. The invention illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms "comprising", "including", "containing", etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such
terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the inventions embodied therein herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention.
The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.
Other embodiments are within the following claims and non- limiting examples. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.
Working Examples
I. Materials
Meropenem trihydrate and tigecycline were purchased from Afine Chemical (Hangzhou, Zhejiang, China).
Rifampicin was obtained from Leshan Sanjiu-Longmarch Pharmaceuticals Co., Ltd.
Colistin sulfate was purchased from Sigma Chemical Co. (Louis, MO, USA).
Clinical isolates of multidrug resistant bacteria used in the study were obtained from the National University Hospital, Singapore and included Pseudomonas aeruginosa PSE2 (resistant to ciprofloxacin, aminoglycosides, carbapenems), Klebsiella pneumoniae ENT443 (resistant to ciprofloxacin and carbapenems), Escherichia coli EC424 (resistant to ciprofloxacin, carbapenems), Acinetobacter baumannii AB1 (resistant to ciprofloxacin,
aminoglycosides, carbapenems), Mueller-Hinton broth (Oxoid, Bashingstoke, UK) was used as the culture media for the antimicrobial activity test.
II. Methods
Preparation of Spray-Dried Powders Powders of colistin (SD-COL), meropenem (SD-MEM), rifampicin (SD-RIF), tigecyline (SD-TGC), ternary combination powders of colistin/meropenem/rifampicin (SD- COL/MEM/RIF) in weight ratio of 5:4: 12, colistin/meropenem/tigecycline (SD- COL/MEM/TGC) in weight ratio of 5:4:4 and colistin/tigecycline/rifampicin (SD- COL/TGC/RIF) in weight ratio of 5:4: 12 were prepared by spray drying the ethanol-water co-solvent feedstock of antimicrobials agent(s) on a B-90 Nano Spray Dryer (Biichi Labortechnik AG, Flawil, Switzerland) with operating parameters as detailed in table 2. The drug ratios developed were first derived from in vitro susceptibility studies against control strains and guided by EUCAST (European Committee on Antimicrobial Susceptibility Testing) susceptibility breakpoints. The spray-dried powders were stored in a desiccator at room temperature for further characterization. Colistin sulfate (instead of colistimethate sodium) is chosen as colistin sulfate is more stable than colistimethate sodium in human plasma.
[Table 2]
Spray drying parameters
Spray mesh size (μιη) 5.5
Feed concentration (w/v %) 0.65
Co-solvent (DI watenethanol) ratio (v/v) 2: 1
Nitrogen flow rate (L/min) 120
Relative spray rate (mL/h) 4
Inlet Temperature (°C) 120
Outlet Temperature (°C) 60-65
Yield (%) 80-90
Surface morphology
The morphology of the powder particles was examined by a field emission scanning electron microscopy (FESEM, JEOL JSM-6700) at 5 kV. Prior to imaging, the samples were dispersed onto carbon sticky tabs and coated with gold for 80 seconds using a sputter coater (Cressington 208HR, Watford, UK).
Particle size analysis
The particle size distribution of the spray-dried powders was determined by laser diffraction on the Malvern Mastersizer 2000 (Malvern Instruments, UK) using the Scirocco dry dispersion unit. The powders were dispersed in triplicates at 3 bars of pressure using refractive indices (RI) of 1.575 for SD-COL and SD-COL/MEM/TGC, 1.639 for SD-MEM, 1.675 for SD-TGC, and 1.613 for SD-RIF, SD-COL/MEM/RIF and SD-COL/TGC/RIF.
Powder crystallinity
Powder crystallinity of the samples was assessed by powder X-ray diffraction (pXRD) at room temperature using an X-ray diffractometer (D8 Advance; Bruker AXS GmbH, Karlsruhe, Germany). Samples were scanned from 5-45° (2Θ) with an angular increment of 0.04° and at 1 s per step using Cu Ka radiation generated at 35 kV and 40 niA.
Surface area determinations
The specific surface area of the spray-dried powders was determined by a surface area analyzer (Micromeritics ASAP 2420, USA), using nitrogen as the adsorbate gas. Samples were degassed at 25°C for 24 h on a vacuum dryer, prior to the measurements. The specific surface area was then determined by the multipoint Brunauer-Emmett-Teller (BET) gas adsorption/desorption method.
In vitro aerosol performance
The aerosol performance of the spray-dried powders was assessed using a Next Generation Impactor (NGI, Copley Scientific, Nottingham, UK) coupled with a United States Pharmacopoeia (USP) stainless steel throat in a walk-in environmental chamber (Synersys, Singapore) maintained at 25 °C and 40% RH. The method followed the procedure specified for DPIs in the British Pharmacopoeia (2009). Prior to testing, all the eight impactor stages
were sprayed with MOLYKOTE® 316 silicone grease release spray (Dow Corning Corp., Midland, MI) to minimize particle bounce. Approximately 10 mg of powder from each formulation was filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3, Capsugel®, New Jersey, USA), loaded into an Aerolizer® inhaler (Novartis Pharmaceuticals, Basel, Switzerland), pierced and then actuated for 4 s at 60 L/min. Six capsules were fired per experiment, delivering a total dose of 60 mg. The flow through the NGI was measured using a calibrated flow meter (TSI Model 4040C, TSI Instrument Ltd., Buckinghamshire, UK), controlled by a high capacity vacuum pump (Model HCP5, Copley Scientific, Nottingham, UK) and a critical flow controller (TPK 2000, Copley Scientific, Nottingham, UK). After actuation, the device, capsule, throat and each part of the NGI were washed separately and thoroughly using ethanol-water co-solvent. The solutions were then assayed by high performance liquid chromatography (HPLC) after appropriate sample dilutions were made. Each dispersion test was performed in triplicates to obtain mean values. At a flow rate of 60 L/min, the aerodynamic cut-off diameters of stages 1, 2, 3, 4, 5, 6 and 7 are 8.06, 4.46, 2.82, 1.66, 0.94, 0.55 and 0.34 μιη. Particles with diameter size less than 0.34 μιη were captured on a Micro Orifice Collector (MOC) beyond stage 7.
Fine particle fraction (FPF) represents the mass fraction of drug particles smaller than 5 μηι in the aerosol cloud (FPD) relative to the total mass recovered and was obtained by interpolation to the cumulative percent undersize at 5 μιη. FPF (emitted) was obtained when the FPD was expressed relative to the ED.
Drug content quantification
Drug contents in the spray-dried powders and in the aliquots collected from the NGI were analyzed via HPLC (1100 series, Agilent Technologies, CA, USA). Assay of colistin was conducted via the use of a Zorbax SB C-18 column (4.6 mm x 150 mm, 3.5 μιη) (Agilent Technologies, CA, USA). The mobile phase consisted of 0.05% (v/v) TFA aqueous solution (solvent A) and acetonitrile (solvent B), delivered at 1 mL/min under a linear gradient: 0-8 min, 80% to 64% A; 8-10 min, 64% A to 80% A. Colistin peak appeared at a retention time of 5.3 min under a UV wavelength of 214 nm. A Zorbax Extend C-18 column (4.6 mm x 150 mm, 3.5 μιη) (Agilent Technologies, CA, USA) was used as the stationary phase for simultaneous assays of meropenem, tigecyline and rifampicin. The chromatograph separation was performed using a gradient mobile phase system starting with 95:5 solvent A (95% 50
niM ammonium acetate, pH 6.2-5% acetonitrile): B (5% 50 mM ammonium acetate, pH 6.2- 95% acetonitrile) changed to 50:50 solvent A:B over 10 min then ramped to 5:95 solvent A:B in 1 min. A 2-min isocratic hold was followed by a step back to the initial conditions. A UV absorbance wavelength of 244 nm was employed for the simultaneous detection of meropenem, tigecyline and rifampicin at retention times of 1.7 and 5.7 and 10.6 min, respectively.
Antimicrobial activity of ternary formulation of cotistin combinations
In vitro antimicrobial activity of the spray-dried powders was determined quantitatively via time-kill studies. Overnight cultures of the test organism was diluted in Mueller-Hinton broth (MHB) to give a starting bacterial density of approximately 5 x 105 CFU/ml. Spray-dried powders were added to the cultures such that the final concentrations were at 1 x MIC. The cultures were then incubated at 37°C with shaking. Bacterial cell counts were estimated at time 0 and 24 hr. A synergistic result was defined as a ^2 logio decrease in colony count after 24 h by the combination compared to the most active single agent, and additivity as a 1 to <2 logio decrease in colony count after 24 h by the combination compared to the most active single agent, and indifference as a <1 logio increase or decrease in colony count after 24 h by the combination compared with that by the most active single agent.
III. Results
The schematic diagram of figure 1 illustrates the different mechanisms of action in the representative ternary compositions of the present invention.
[Table 3]
Individual Effect on Ternary drug drug Drug class bacteria Mode of action combinations
(drug ratio by weight %)
Colistin
(COL) Polymyxin Bactericidal Disruption of cell membrane
Meropene Carbapene Inhibition of peptidoglycan COL/MEM/TG m (MEM) m Bactericidal synthesis C (5:4:4)
Rifampicin Inhibition of RNA COL/MEM/RIF (RIF) Ansamycin Bactericidal transcription (5:4: 12)
Tigecyclin Tetracyclin Bacteriostatic Inhibition of protein COL/TGC/RIF
e (TGC) e synthesis (5:4: 12)
Prior to the present invention, the commercial and conventional antibiotic dry powder inhaler formulations, included Novartis® TIP (Tobramycin Inhaled Powder) and Forest Laboratories® Colobreathe (Colistin Inhaled Powder).
The antibiotic combinations described in table 3, were prepared by co- spray drying the ternary system containing colistin sulphate and two other antibiotics (tigecycline, rifampicin or meropenem trihydrate) and were prepared in the weight ratios illustrated in table 4 using the Nano Spray Dryer B-90. Table 4 illustrates that the antibiotic combinations are shown to be therapeutically effective against multi-drug resistant Pseudomonas aeruginosa, and specifically a synergistic effect was exhibited by the antibiotic combinations.
[Table 4]
Table 4 legend: COL, colistin; MEM, meropenem; TGC, tigecycline; RIF, rifampicin; GEN, gentamicin. a Values represent the logio change in CFU/ml in the time kill assay after 24-h exposure to the ternary spray-dried formulations compared to the most active drug.
The ternary dry powder compositions (Figure 2) consisted of respirable- sized particles (dso ~ 3 μιη) capable of achieving high fine particle fractions (FPF) (out of the total dose) of approximately 52-69% and emitted fine particle fractions (FPF(emitted)) of approximately 58-73% (See Table 5 and Table 6).
[Table 5]
[Table 6]
The results outlined in Tables 5 and 6 show that the composition of the present invention when formulated as a multi-component particle, are able to achieve the 'same particle size' for each drug (i.e. 3 drugs in a single entity), which leads to more uniform drug deposition for each drug, with advantageous implications in terms of therapeutic efficacy.
As illustrated in Figures 3-5, a concomitant and uniform in vitro deposition profile is achieved for the antibiotic combinations across all impaction stages when dispersed at 60 L/min. Specifically, the time-kill assay showed a synergism, > -21ogio change, against resistant Pseudomonas aeruginosa for the three ternary combinations in their co-spray dried form, see Table 4.
As it will be appreciated, the above results and three ternary combinations are potentially useful for patients suffering from cystic fibrosis, bronchiectasis, pneumonia and other bacteria-associated respiratory disorders.
Moreover, the three ternary combinations are also shown to be effective (i.e. additive or indifferent interactions) against resistant A. baumannii, K. pneumoniae and E. coli. In particular, SD-COL/TGC/RIF exhibited a favourable 'additive' interaction against multi-drug resistant K. pneumonia and E. coli, see Table 7.
In this regard, synergy is defined as a ^2 logio decrease in colony count after 24 h by the combination compared to the most active single agent, additivity as a 1 to <2 logio decrease in colony count after 24 h by the combination compared to the most active single agent and indifference as a <1 logio increase or decrease in colony count after 24 h by the combination compared with that by the most active single agent.
[Table 7]
Resistant bacterial strain Drug Ratio Time-kill Interaction
(Resistance profile) assay
COL MEM TGC RIF (log lo
change)a
Klebsiella pneumoniae
ENT 443 (CIPR MEMR)*
SD-COL/TGC/RIF 5 - 4 12 -1.2 Additivity
SD-COL/MEM/TGC 5 4 4 - 0.1 Indifference
SD-COL/MEM/RIF 5 4 - 12 0.0 Indifference
Escherichia coli EC424
(CIPRMEMR)*
SD-COL/TGC/RIF 5 - 4 12 -1.0 Additivity
SD-COL/MEM/TGC 5 4 4 - 0.1 Indifference
SD-COL/MEM/RIF 5 4 - 12 0.2 Indifference
Acinetobacter baumannii
AB 1 (CIPR GENR MEMR)
SD-COL/TGC/RIF 5 - 4 12 -0.5 Indifference
SD-COL/MEM/TGC 5 4 4 - 0.2 Indifference
SD-COL/MEM/RIF 5 4 - 12 0.2 Indifference
Table 7 legend: COL, colistin; MEM, meropenem; TGC, tigecycline; RIF, rifampicin; CIP, ciprofloxacin; GEN, gentamicin. * Isolate bears a carbapenemase which results in enzymatic hydrolysis of carbapenems conferring carbapenem resistance. a Values represent the logi0 change in CFU/ml in the time kill assay after 24-h exposure to the ternary spray-dried formulations compared to the most active drug.
[Table 8]
The ternary spray-dried combination powders presented broad diffused diffraction patterns which are characteristic of amorphous materials (similar to their spray-dried individual species), as shown in figure 7. In this regard, it will be appreciated that spray dried powders are typically amorphous.
IV. Discussion
The results described herein, illustrated several benefits of the compositions of the present invention. Firstly, from the microbiological standpoint, the compositions prevent the emergence of bacterial drug resistance as the simultaneous development of resistance towards multiple drug classes is remote; and secondly from a patient management standpoint, combinations comprising colistin have the potential to reduce colistin toxicity by allowing a lowered therapeutic dose. This is achieved via a synergistic or additive interaction of colistin with its partner antibiotics.
When the route of administration of the composition and combination of antibiotics is considered, inhaled delivery of colistin combinations is shown to be effective in eradicating multi-drug resistant (MDR) pathogens as it directly targets the foci of infection. In this regard, elevated drug concentrations can be achieved locally at the site of lung infection without the adverse effects of systemic toxicity. Moreover, a dry powder inhaler (DPI) formulation is superior over the other aerosol delivery modes (for example, a nebuliser or metered dose inhaler (MDI) in terms of stability, delivery efficiency, portability, ease-of-use and the avoidance of undesired precipitation in solutions.
Rifampicin is a bactericidal antibiotic drug of the ansamycin group that has been used to prevent and treat tuberculosis and other infections, but has very limited use in monotherapy that may be due to the rapid emergence of resistance. Meropenem is a member of the carbapenem class of antibiotics that is active against a broad spectrum of Gram-positive and Gram- negative pathogens, including the beta-lactamase producers. However, the worldwide spread of drug resistance to carbapenem antibiotics is seriously threatening this class of life- saving drugs. Tigecycline, had been approved by the Food and Drug Administration (FDA) in 2009 for the treatment of community-acquired pneumonia, and was considered a useful alternative against carbapenem-resistant bacteria. However, its clinical efficacy, especially in severe infections, is problematic, and without being bound by theory may be due to its subdued bacteriostatic action of inhibiting growth, low serum levels and the heightened propensity for resistance development.
Accordingly, the working examples disclosed herein explored the combinations of colistin, rifampicin, meropenem and tigecycline for their potential use as combinational therapies. In this regard, spray-dried ternary combination particles of these antibiotics were produced, wherein both SD-COL/MEM/RIF and SD-COL/TGC/RIF had crumpled sheet-like structures, whereas SD-COL/MEM/TGC was a mixture of corrugated spherical particles and irregularly- shaped chips (Figure. 2). The similarity in surface morphologies of both SD-COL/MEM/RIF and SD-COL/TGC/RIF to SD-RIF may be due to the dominance of rifampicin in the spray- dried ternary combination particles, which resulted in its prevailing influence on their particle morphologies. The specific surface areas of the ternary spray-dried formulations containing
rifampicin (i.e. SD-COL/MEM/RIF and SD-COL/TGC/RIF) were significantly higher than the rifampicin-void spray-dried formulation (i.e. SD-COL/MEM/TGC). This could be due to the former's crumpled sheet-like particle structure, which minimized aggregation and promoted high specific surface areas. For these formulations, the dispersibilities obtained were generally robust (i.e. FPFs ranging from 52.8 + 2.5% to 69.5 + 5.0%), thus suggesting the favourability of the corrugated/crumpled particle morphology in aerodynamics. These particles have high free volume with pockets of void space and hence have low densities, are aggregation-resistant, and have reduced inter-particle contact areas. Airflow of 60 L/min was used to simulate the reduced inspiratory effort achieved by patients with compromised lung functions due to pneumonia or cystic fibrosis as examples. Generally, all the single and ternary spray-dried formulations disclosed herein displayed robust delivery efficiency with FPFs ranging from 42.6 + 1.6% to 69.5 + 5.0% (Table 6), whereinan FPF value that is significantly higher than 30% is an index of good aerosol performance. In particular, among the single spray-dried formulations, SD-MEM was found to have a slightly lower FPF of 42.6 + 1.6% when compared to the others (i.e. FPFs > 50%). The lower FPF might be due to the cohesiveness of the powder, which could in a way be inferred by the formulation's high capsule and device retention (i.e. 12.6 ± 2.8% and 29.0 ± 2.9%, respectively (Fig. 6b)). Favourably, when meropenem was formulated as a ternary mix (i.e. SD-COL/MEM/TGC and SD-COL/MEM/RIF), the cohesiveness of meropenem was minimized. Capsule and device retention had decreased significantly to fewer than 5% and 7%, respectively (Fig. 4 and 5). Clearly, it does seem that formulating the drugs into a ternary mix has the advantage of ameliorating the performance of the poorer-performing species. For the ternary spray-dried formulations (i.e. SD-COL/MEM/TGC, SD-COL/MEM/RIF and SD- COL/TGC/RIF), there was concomitant deposition observed across all stages, including the throat, inhaler and capsule, thus suggesting uniformity in the powder and/or aerosol (Fig. 3- 5). Furthermore, all three ternary formulations are highly suited for delivery via the aerosol route in view of the robust FPFs obtained (Table 6). Improvements to the emitted fraction (i.e. inferred via closely similar FPF and FPF (emitted)) were also achieved in the ternary species which again reinforces the benefits of co-delivery.
The antimicrobial activities of the ternary spray-dried powder composition (i.e. SD- COL/MEM/TGC, SD-COL/MEM/RIF and SD-COL/TGC/RIF) were tested against different MDR pathogenic respiratory bacteria and summarized in Tables 4 and 7. In essence, the formulations were all capable of eradicating resistant bacteria. When all three ternary formulations were tested against MDR Pseudomonas aeruginosa that was resistant to ciprofloxacin (fluoroquinolone group), gentamicin (aminoglycoside group) and meropenem (carbapenem group), a synergistic kill was obtained across the formulations, with logio CFU changes of -4.0, -3.6 and -3.2 for SD-COL/TGC/RIF, SD-COL/MEM/TGC and SD- COL/MEM/RIF, respectively, after a 24h test period. With a synergistic interaction, a much reduced drug dose would be required to achieve the same therapeutic effect as conventional monotherapy.
The above results are applicable to both combinatorial and local delivery strategies (directly to the lungs), which also served to reduce the required drug dose into the body. In totality, a synergistic inhaled combination would not only minimize the toxic side effects of the antibiotics, but also help in the minimization of drug resistance. Although carbapenem- resistant bacteria is currently the bane of patients and medical practitioners worldwide and has limited treatment options, it is nevertheless important to note that meropenem (i.e. a carbapenem) is still relevant and potent in killing these resistant bacteria when applied in a combinatorial composition. Indeed, the results and compositions disclosed herein may have positive implications in terms of extending the drug's useful 'lifespan'. Both SD- COL/MEM/RIF and SD-COL/MEM/TGC (carbapenem(MEM)-containing formulations) could not only eliminate all four species of carbapenem-resistant bacteria, but also elucidate a synergistic response for the MDR Pseudomonas aeruginosa isolate.
Among the ternary combination disclosed herein, SD-COL/TGC/RIF (non-carbapenem (MEM)-containing combination) was found to be the best performing species. Not only did this ternary combination exhibit a synergistic interaction against carbapenem-resistant Pseudomonas aeruginosa, but also revealed additive interactions against other carbapenem- resistant Gram-negatives such as Klebsiella pneumoniae and Escherichia coli. Although an additive interaction might be slightly lower than a synergistic interaction, they are
nonetheless still useful and advantageous in dosage reduction, which could help in the minimization of the associated side effects and the potential for bacterial resistance.
The superior qualities of SD -COL/TGC/RIF (over SD-COL/MEM/RIF and SD- COL/MEM/TGC) may be attributed to colistin, tigecycline and rifampicin's distinct killing mechanisms which targeted different functions of the bacterial cell (Table 3 and Figure 1). Bactericidal colistin is a cationic antibiotic that binds to the anionic lipopoly saccharide (LPS) of Gram-negative bacteria's membrane, leading to a disruption of the membrane permeability, leakage of intracellular content and hence cell death. Perturbation of the bacterial cellular membrane integrity by colistin may in turn favour the uptake of tigecycline and rifampicin to effect a 'collaborative' synergistic interaction. Bactericidal rifampicin's mechanism of action is based on its ability to specifically bind and inhibit the bacterial DNA- dependent RNA polymerase. On the other hand, bacteriostatic tigecycline works by binding to the 30S subunit of the bacterial ribosome, thus inhibiting peptide elongation and subsequently, disrupting protein synthesis. As each of colistin, rifampicin and tigecycline have a unique complementary mode of action that is not shared by any other antibiotic in the combination, it is therefore encouraging to observe a number of favourable interactions arising from the SD- COL/TGC/RIF species,as compared to SD-COL/MEM/RIF and SD-COL/MEM/TGC. For SD-COL/MEM/RIF and SD-COL/MEM/TGC, as they have two antibiotics, meropenem and colistin, with overlapping actions on the bacterial cell wall (Figure 1), their 'collaborative' efficiency is therefore understandably, slightly lower than SD-COL/TGC/RIF. Regular use of antibiotics, be it monotherapy or combination therapy, will eventually lead to resistance. The advantage of the present invention and combination of antibiotics lies in the potential for 'rotational therapy' (i.e. treatment rotated between the three different-member combinations). Recalcitrant bacterial infections that require prolonged antibiotic treatment could benefit from such a therapy while enjoying the reduced risk of antimicrobial resistance. With three unique combinations involving three different complementary antibiotics, the possibility of a bacterium developing resistance to all the antibiotics and combinations simultaneously would hence be very far remote.
As such, the present invention and results demonstrated herein provide a 'toolbox' of DPI compositions (for example, COL/TGC/RIF, COL/MEM/RIF and COL/MEM/TGC) to successfully fight against respiratory 'superbugs' . The benefits of co-delivery include the potential for synergy which helps to further lower the toxic drug dose and the associated side effects (i.e. colistin), ameliorating the performance of a poorer-performing species (i.e. meropenem), the life-span extension of 'expiring/redundant' antibiotics (i.e. meropenem, rifampicin and tigecycline) and the opportunity to mount a collaborative and concerted mode of attack on bacteria (i.e. COL/TGC/RIF).
Moreover, compared to nebulised antibiotics, the DPI compositions do not require a bulky nebuliser, are easier and quicker to use, and provide much better formulation stability as it is formulated as a powder. Furthermore, the DPI compositions are capable of a high FPF of -52-69%, much higher than that achieved via the traditional nebuliser (-10%).
In summary, the compositions of the present invention, and the therapeutic effect of the antibiotic combinations was shown to be advantageous. In addition to the responses against resistant P. aeruginosa, the compositions were also capable of killing resistant A. baumannii, K. pneumonia and E. coli bacteria with either an indifferent or additive interaction. Therefore, the development of the compositions disclosed herein is indeed a novel and timely intervention in the fight against multi-resistant pathogenic respiratory bacteria.
Claims
1. A dry powder composition comprising: a polymyxin antibiotic; and at least one further antibiotic selected from the group consisting of an aminoglycoside, an ansamycin, a carbacephem, a carbapenem, a cephalosporin, a glycopeptide, a lincosamide, a lipopeptide, a macrolide, a monobactam, a nitrofuran, a oxazolidonone, a penicillin, a polypeptide, a quinolone, a sulfonamide, a tetracycline, a chloramphenicol, a phosphonic acid antibiotic and a mycobacteria antibiotic.
2. The dry powder composition of claim 1 , wherein the polymyxin is colistin.
3. The dry powder composition of claim 1 or 2, wherein the at least one further antibiotic is selected from the group consisting of a carbapenem, an ansamycin and a tetracycline.
4. The dry powder composition of any one of claims 1 to 3, wherein the carbapenem is selected from the group consisting of ertapenem, doripenem, imipenem and meropenem.
5. The dry powder composition of claim 4, wherein the carbapenem is meropenem.
6. The dry powder composition of any one of claims 1 to 3, wherein the ansamycin is rifampicin.
7. The dry powder composition of any one of claims 1 to 3, wherein the tetracycline is selected from the group consisting of demeclocycline, doxycycline, minocycline, oxytetracycline and tetracycline analogues.
8. The dry powder composition of claim 7, wherein the tetracycline is tigecycline.
9. The dry powder composition of any one of claims 1, 2, 3, 6, 7 or 8, wherein the composition comprises colistin, tigecycline and rifampicin.
10. The dry powder composition of any one of claims 1, 2, 3, 4, 5, 7 or 8, wherein the composition comprises colistin, meropenem and tigecycline.
11. The dry powder composition of any one of claims 1, 2, 3, 4, 5, 6 or 8, wherein the composition comprises colistin, meropenem and rifampicin.
12. The dry powder composition according to claim 9, wherein the weight ratio of colistin, tigecycline and rifampicin is 5:4: 12.
13. The dry powder composition according to claim 10, wherein the weight ratio of colistin, meropenem and tigecycline is 5:4:4.
14. The dry powder composition according to claim 11, wherein the weight ratio of colistin, meropenem and rifampicin is 5:4: 12.
15. The dry powder composition of any one of claims 1-14, wherein the dry powder has a fine particle fraction of at least 50%.
16. The dry powder composition of claim 15, wherein the particle size is in the range of 1 to 10 μιτι.
17. The dry powder composition of any one of claims 1-16, wherein the composition is formulated to be administered nasally, orally, transdermally, subcutaneously or intravenously.
18. The dry powder composition of any one of claims 1-16, wherein the composition is formulated to be administered by an inhaler, a syringe, an implantable device, a medically inserted device or a biomaterial.
19. The dry powder composition of any one of claims 1-18, wherein the composition comprises one or more components selected from the group consisting of excipients, antibiotics, a pharmaceutically acceptable carrier, a mucolytic agent, an antiinflammatory agent, and pharmaceutically active ingredients.
20. The use of a dry powder composition of any one of claims 1-19 in the manufacture of a medicament for treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium.
21. The use of claim 20, wherein the bacterium is a Gram-negative bacteria.
22. The use of claim 21, wherein the Gram-negative bacteria is selected from the group consisting of, Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii- calcoaceticus complex and Mycobacterium species.
23. The use of a dry powder composition of any one of claims 1-19 in the manufacture of a medicament for treating a respiratory system infection by a bacterium.
24. The use of claim 23, wherein the bacterium is a multidrug resistant bacterium.
25. The use of claim 24, wherein the multidrug resistant bacterium is selected from the group consisting of Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumonia and Escherichia coli.
26. The use of any one of claims 23 to 25, wherein the bacterial respiratory system infection is laryngitis, bronchitis, pneumonia, or sinusitis
27. The use of a dry powder composition of any one of claims 1-19 in the manufacture of a medicament for treating a pulmonary disease or condition.
28. The use of claim 27, wherein the pulmonary disease or condition is cystic fibrosis, bronchiectasis, or chronic obstructive pulmonary disease (COPD).
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/329,244 US10953070B2 (en) | 2014-07-25 | 2015-07-24 | Antibiotic compositions for treating bacterial infections |
SG11201700621XA SG11201700621XA (en) | 2014-07-25 | 2015-07-24 | Antibiotic compositions for treating bacterial infections |
US17/175,525 US11883460B2 (en) | 2014-07-25 | 2021-02-12 | Antibiotic compositions for treating bacterial infections |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201404407X | 2014-07-25 | ||
SG10201404407X | 2014-07-25 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/329,244 A-371-Of-International US10953070B2 (en) | 2014-07-25 | 2015-07-24 | Antibiotic compositions for treating bacterial infections |
US17/175,525 Division US11883460B2 (en) | 2014-07-25 | 2021-02-12 | Antibiotic compositions for treating bacterial infections |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016013986A1 true WO2016013986A1 (en) | 2016-01-28 |
Family
ID=55163402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SG2015/050235 WO2016013986A1 (en) | 2014-07-25 | 2015-07-24 | Antibiotic compositions for treating bacterial infections |
Country Status (3)
Country | Link |
---|---|
US (2) | US10953070B2 (en) |
SG (1) | SG11201700621XA (en) |
WO (1) | WO2016013986A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018035183A1 (en) * | 2016-08-16 | 2018-02-22 | University Of Rochester | Pharmaceutical composition containing polymyxin b/trimethoprim based therapeutics |
US20190328669A1 (en) * | 2018-04-26 | 2019-10-31 | Purdue Research Foundation | Co-spray drying of meropenem and colistin and the uses thereof |
WO2020119959A1 (en) * | 2018-12-14 | 2020-06-18 | Galenus G.H. Ag | Pharmaceutical composition for the treatment of cystic fibrosis |
WO2020239696A1 (en) * | 2019-05-24 | 2020-12-03 | Stichting Katholieke Universiteit | Improved administration of glycylcyclines by inhalation |
EP3582786A4 (en) * | 2017-01-09 | 2020-12-23 | Rempex Pharmaceuticals, Inc. | Co-administration of minocycline and colistin to reduce acute kidney injury |
WO2022094079A1 (en) * | 2020-10-28 | 2022-05-05 | The Trustees Of Dartmouth College | Methods of treating cystic fibrosis |
WO2022153045A1 (en) * | 2021-01-12 | 2022-07-21 | Quadram Institute Bioscience | Methods and compositions for antibiotic potentiation |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11110085B2 (en) * | 2018-04-26 | 2021-09-07 | Purdue Research Foundation | Co-spray drying of ciprofloxacin and colistin and the uses thereof |
JP2022526495A (en) * | 2019-03-18 | 2022-05-25 | シーダーズ-サイナイ・メディカル・センター | Compositions and Methods for Treating Gastrointestinal Diseases and Disorders |
WO2021117065A1 (en) * | 2019-12-14 | 2021-06-17 | Manu Chaudhary | Formulations of polybasic drugs to reduce multi-organ toxicity |
US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
WO2022236088A1 (en) * | 2021-05-06 | 2022-11-10 | Bioharmony Therapeutics Inc. | Lysin polypeptide compositions and methods of use |
CN114617952B (en) * | 2022-01-19 | 2022-09-02 | 暨南大学 | Polymyxin B sulfate/raffinose dry powder and inhalation powder aerosol thereof and preparation method |
WO2024091863A1 (en) | 2022-10-25 | 2024-05-02 | Starrock Pharma Llc | Combinatorial, and rotational combinatorial therapies for obesity and other diseases |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012061902A1 (en) * | 2010-11-12 | 2012-05-18 | Monash University | Micronised spray-dried particles comprising polymyxin |
WO2013011019A1 (en) * | 2011-07-21 | 2013-01-24 | Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum | Pharmaceutical composition for treating a respiratory disease |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1129705A1 (en) | 2000-02-17 | 2001-09-05 | Rijksuniversiteit te Groningen | Powder formulation for inhalation |
US20050065141A1 (en) * | 2003-07-31 | 2005-03-24 | Odink Debra A. | Carbapenems useful in treating and preventing pulmonary infections, pharmaceutical compositions thereof and modes of administration thereof |
PT106094A (en) | 2012-01-13 | 2013-07-15 | Hovione Farmaciencia S A | ADMINISTRATION BY INHALATION OF FORMULATIONS WITH HIGH DOSE |
AU2013203774A1 (en) * | 2012-01-27 | 2013-08-15 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Compositions and methods for immunization against bacteria expressing a carbapenemase |
US10105500B2 (en) * | 2012-05-09 | 2018-10-23 | Virginia Commonwealth University | Dry powder inhaler (DPI) designs for producing aerosols with high fine particle fractions |
CN103110633B (en) | 2013-02-28 | 2014-08-20 | 郑州大学 | Dry powder inhalant capable of preventing mycobacterium tuberculosis from transmitting through respiratory tract |
-
2015
- 2015-07-24 WO PCT/SG2015/050235 patent/WO2016013986A1/en active Application Filing
- 2015-07-24 US US15/329,244 patent/US10953070B2/en active Active
- 2015-07-24 SG SG11201700621XA patent/SG11201700621XA/en unknown
-
2021
- 2021-02-12 US US17/175,525 patent/US11883460B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012061902A1 (en) * | 2010-11-12 | 2012-05-18 | Monash University | Micronised spray-dried particles comprising polymyxin |
WO2013011019A1 (en) * | 2011-07-21 | 2013-01-24 | Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum | Pharmaceutical composition for treating a respiratory disease |
Non-Patent Citations (3)
Title |
---|
BIANCOFIORE, G. ET AL.: "Colistin, meropenem and rifampin in a combination therapy for multi-drug-resistant Acinetobacter baumannii multifocal infection - A case report", MINERVA ANESTESIOLOGICA, vol. 73, 2007, pages 181 - 185 * |
HENG, D. ET AL.: "Synergistic Combination Dry Powders for Inhaled Antimicrobial Therapy", POWDERS AND GRAINS, 2013, AIP CONFERENCE PROCEEDINGS, vol. 1542, pages 113 - 116 * |
ZHOU, Q ET AL.: "Synergistic Antibiotic Combination Powders of Colistin and Refampicin Provide High Aerosolization Efficiency and Moisture Protection", THE AAPS JOURNAL, vol. 16, no. 1, 16 October 2013 (2013-10-16), pages 37 - 47 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018035183A1 (en) * | 2016-08-16 | 2018-02-22 | University Of Rochester | Pharmaceutical composition containing polymyxin b/trimethoprim based therapeutics |
CN109789125A (en) * | 2016-08-16 | 2019-05-21 | 罗切斯特大学 | Contain the pharmaceutical composition for being based on polymyxin B/trimethoprim therapeutic agent |
US11096923B2 (en) | 2016-08-16 | 2021-08-24 | University Of Rochester | Pharmaceutical composition containing polymyxin B/trimethoprim based therapeutics |
AU2017313733B2 (en) * | 2016-08-16 | 2022-11-17 | University Of Rochester | Pharmaceutical composition containing polymyxin B/trimethoprim based therapeutics |
EP3582786A4 (en) * | 2017-01-09 | 2020-12-23 | Rempex Pharmaceuticals, Inc. | Co-administration of minocycline and colistin to reduce acute kidney injury |
US20190328669A1 (en) * | 2018-04-26 | 2019-10-31 | Purdue Research Foundation | Co-spray drying of meropenem and colistin and the uses thereof |
US11278497B2 (en) * | 2018-04-26 | 2022-03-22 | Purdue Research Foundation | Co-spray drying of meropenem and colistin and the uses thereof |
WO2020119959A1 (en) * | 2018-12-14 | 2020-06-18 | Galenus G.H. Ag | Pharmaceutical composition for the treatment of cystic fibrosis |
WO2020239696A1 (en) * | 2019-05-24 | 2020-12-03 | Stichting Katholieke Universiteit | Improved administration of glycylcyclines by inhalation |
WO2022094079A1 (en) * | 2020-10-28 | 2022-05-05 | The Trustees Of Dartmouth College | Methods of treating cystic fibrosis |
WO2022153045A1 (en) * | 2021-01-12 | 2022-07-21 | Quadram Institute Bioscience | Methods and compositions for antibiotic potentiation |
Also Published As
Publication number | Publication date |
---|---|
US20210236589A1 (en) | 2021-08-05 |
US10953070B2 (en) | 2021-03-23 |
US11883460B2 (en) | 2024-01-30 |
SG11201700621XA (en) | 2017-02-27 |
US20170209530A1 (en) | 2017-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11883460B2 (en) | Antibiotic compositions for treating bacterial infections | |
US10792289B2 (en) | Use of aerosolized levofloxacin for treating cystic fibrosis | |
KR101959873B1 (en) | Aerosol fluoroquinolone formulations for improved pharmacokinetics | |
CN105163785A (en) | Methods for treating respiratory diseases and formulations therefor | |
WO2015058087A1 (en) | Methods for treating lung infections and inflammation | |
EP1732527A2 (en) | Use and administration of bacterial efflux pump inhibitors | |
US20120237564A1 (en) | Use of Aerosolized Antibiotics for Treating Chronic Obstructive Pulmonary Disease | |
EP2504013A1 (en) | Inhaled fosfomycin/tobramycin for the treatment of chronic obstructive pulmonary disease | |
Boyarchuk et al. | Perspectives of the inhaled antibiotics usage in pediatrics | |
AU2015275224C1 (en) | Use of aerosolized levofloxacin for treating cystic fibrosis | |
WO2022256464A1 (en) | Compositions of clofazimine and amikacin for pulmonary administration in the treatment of respiratory diseases | |
ANTI-INFECTIVES | ADVANCES IN PULMONARY DELIVERY OF INHALED ANTI-INFECTIVES | |
WO2012103116A1 (en) | Pulmonary administration of rifalazil and analogs thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15825144 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15329244 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15825144 Country of ref document: EP Kind code of ref document: A1 |